UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
UCSFCancerCenter_AACR2017_Brochure
UCSFCancerCenter_AACR2017_Brochure
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>UCSF</strong> <strong>HELEN</strong> <strong>DILLER</strong><br />
<strong>FAMILY</strong> <strong>COMPREHENSIVE</strong><br />
<strong>CANCER</strong> <strong>CENTER</strong><br />
American Association for Cancer Research Annual Meeting<br />
April 1 – 5, 2017<br />
Washington, DC<br />
<strong>UCSF</strong> Presentation Brochure<br />
1
Committed to Advancing<br />
Development of Improved<br />
Cancer Therapies, Imaging<br />
Modalities, and Biomarkers<br />
As president of the <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer<br />
Center, one of my key priorities is to initiate and advance programs<br />
that are developing new anticancer drugs making significant impact<br />
on helping cancer patients live longer and better lives. I recognize this<br />
goal is best accomplished by working in partnership with the broader<br />
life science industry. This searchable abstract book of <strong>UCSF</strong> research<br />
presented at AACR is a resource for potential partners interested in<br />
identifying world-class faculty engaged in basic science and clinical<br />
oncology research.<br />
As an NCI-designated comprehensive cancer center, <strong>UCSF</strong> is<br />
recognized for our outstanding science, extensive resources, depth<br />
and breadth of our research in basic, clinical, and population sciences,<br />
as well as cutting edge research that bridges these scientific areas.<br />
Practically, this means that our clinicians and basic scientists work<br />
closely together to (1) identify, develop, and optimize novel therapeutics<br />
for biological efficacy and clinical utility, (2) assess tumor status and<br />
responsiveness to current therapies, (3) develop biomarkers for patient<br />
stratification and therapeutic response, and (4) advance supportive<br />
care options to mitigate the toxicities associated with chemotherapy.<br />
Alan Ashworth, PhD, FRS<br />
President, <strong>UCSF</strong> Helen Diller<br />
Family Comprehensive<br />
Cancer Center<br />
Senior Vice President<br />
for Cancer Services,<br />
<strong>UCSF</strong> Health<br />
Professor of Medicine,<br />
Division of Hematology/<br />
Oncology, Department<br />
of Medicine<br />
<strong>UCSF</strong> is home to many of world’s finest oncology clinicians and<br />
scientists. I invite you learn more about our work and expertise<br />
by reaching out to our faculty during this meeting. If you have any<br />
additional questions or need any assistance with your outreach,<br />
please contact the Director of Strategic Alliances for the Cancer<br />
Center: Cammie Edwards (cammie.edwards@ucsf.edu).<br />
Wishing you a very productive meeting and we look forward to<br />
future discussions and collaborations.<br />
Alan Ashworth, PhD, FRS<br />
President, <strong>UCSF</strong> Helen Diller Family Comprehensive Cancer Center
HDFCCC Overview<br />
A Designated NCI Comprehensive<br />
Cancer Center Since 1999<br />
The “comprehensive” designation—NCI’s highest ranking, awarded only<br />
after a rigorous evaluation process—recognizes <strong>UCSF</strong>’s excellence in<br />
basic research, clinical research, population based research, outreach and<br />
education, and our ability to integrate these diverse research approaches to<br />
cancer and turn them into clinical practice.<br />
Our Success is Driven by Our Faculty<br />
HDFCCC Membership: 415 Members & Affiliate Members<br />
2 Nobel Laureates<br />
3 Albert Lasker Award winners<br />
8 Howard Hughes Medical Investigators<br />
14 Members of the National Academy of Sciences<br />
20 Members of the Institute of Medicine<br />
22 Fellows of the American Academy of Arts and Sciences<br />
6 Fellows of the Royal Society<br />
2
HDFCCC Overview<br />
Working Together Advancing the<br />
Understanding and Treatment of Cancer<br />
Multi-Disciplinary Research Programs<br />
• Breast Oncology<br />
• Cancer Control<br />
• Cancer Genetics<br />
• Cancer, Immunity, and Microenvironment<br />
• Developmental Therapeutics<br />
• Hematopoietic Malignancies<br />
• Neurologic Oncology<br />
• Pediatric Malignancies<br />
• Prostate Cancer<br />
• Tobacco Control<br />
Multi-Disciplinary Clinical Programs<br />
• GU Oncology (non Prostate)<br />
• GI (includes Pancreas Cancer)<br />
• Thoracic Oncology<br />
• Cutaneous Oncology<br />
• Head and Neck Cancer<br />
• Sarcoma<br />
• Endocrine<br />
• Gynecologic Oncology<br />
• Breast Oncology<br />
• Prostate Cancer<br />
Key Initiatives<br />
• Precision Imaging of Cancer and Therapy<br />
• Cancer Immunotherapeutics<br />
• Global Oncology<br />
• Center for BRCA Research<br />
• <strong>UCSF</strong> 500<br />
• Cell Engineering<br />
• Target Validation Initiative<br />
• The San Francisco Cancer Initiative (SF CAN)<br />
Translating Laboratory Discoveries into Improved Patient Care<br />
Whether it is advancing a new vaccine based immunotherapy, developing a new diagnostic<br />
test to distinguish benign moles from malignant melanoma or pioneering new adaptive clinical<br />
trial designs, <strong>UCSF</strong> success in translating laboratory discoveries into improved patient care<br />
comes from its faculty and culture of exploration and collaboration. With over 400 faculty<br />
relentlessly pursuing oncology research and clinical practice, we continue to make significant<br />
strides in understanding the biology of disease and improving patient outcomes with<br />
advanced clinical care.<br />
3
HDFCCC Overview<br />
Core Capabilities<br />
Supporting Our Programs<br />
• Biostatistics<br />
• Clinical Research Support<br />
• Genome Analysis<br />
• Laboratory for Cell Analysis<br />
• Immunohistochemistry & Molecular Pathology<br />
• Mouse Pathology<br />
• Preclinical Therapeutic Testing<br />
• Bio-specimen Banking<br />
• Tobacco Biomarkers<br />
• Bioinformatics<br />
• Computational Biology<br />
Approximately one-quarter of the<br />
University’s ~2,200 full-time faculty<br />
members work in cancer research or<br />
cancer care.<br />
<strong>UCSF</strong> consistently ranks among<br />
the top U.S. biomedical research<br />
organizations in cancer-specific<br />
federal funding. In 2016, <strong>UCSF</strong><br />
received more than $92M from the<br />
National Cancer Institute.<br />
4
Partnering with<br />
<strong>UCSF</strong> HDFCCC<br />
<strong>UCSF</strong> faculty have a long history of working with industry<br />
partners translating discoveries into products that ultimately<br />
improve patient care. We are experienced in establishing and<br />
executing on a wide range of successful partnerships. If you are<br />
interested in learning more about working with the HDFCCC<br />
and its faculty, please contact:<br />
Cammie Edwards, PhD<br />
Director of Strategic Alliances, HDFCCC<br />
• On average, <strong>UCSF</strong> has 200-300 new invention disclosures per year<br />
• An estimated 90 life science start-up companies have been spawned<br />
from the University’s labs, including Genentech, Chiron, and Intellikine<br />
• Included among <strong>UCSF</strong> patents are top revenue producers, such as<br />
- Hepatitis B vaccine<br />
- Bovine growth hormone<br />
- Barrier repair lipids<br />
- Yeast expression vector<br />
- Magnetic resonance imaging<br />
<strong>UCSF</strong> IN THE NEWS (Click on link to read story)<br />
<strong>UCSF</strong>, Pfizer Renew Research Collaboration, Citing Progress in Drug Discovery Research<br />
http://cancer.ucsf.edu/news/2017/01/09/ucsf-pfizer-renew-research-collaboration-citing-progress-in-drug-discovery-research.8092<br />
Search Engine: How Artificial Intelligence Techniques Are Aiding the Hunt for New Drugs<br />
http://cancer.ucsf.edu/news/2017/01/04/search-engine-how-artificial-intelligence-techniques-are-aiding-the-hunt-for-new-drugs.8079<br />
New Targeted Chemotherapy Technology Proves Effective in Mice<br />
http://cancer.ucsf.edu/news/2016/12/12/new-targeted-chemotherapy-technology-proves-effective-in-mice.8063<br />
Mutant Protein Linked to Spread of Lung Cancer within the Body<br />
http://cancer.ucsf.edu/news/2016/11/21/mutant-protein-linked-to-spread-of-lung-cancer-within-the-body.7986<br />
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors<br />
http://cancer.ucsf.edu/news/2016/09/29/cellbots-chase-down-cancer-deliver-drugs-directly-to-tumors.7921<br />
Dr. Amit Sabnis Awarded the 2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer<br />
Research. The award will be used to further his research in identifying the molecular mechanism behind an oncogene-directed<br />
therapy in rhabdomyosarcoma and defining the PAX3-FOXO1 translatome.<br />
5
Presentations<br />
Presentations<br />
View full abstracts on line at:<br />
http://www.abstractsonline.com/pp8/#!/4292<br />
*<strong>UCSF</strong> authors in bold<br />
Saturday, April 1, 2017<br />
Retooling CRISPR to turn genes on and off<br />
Authors*: Luke A. Gilbert<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 8:30 - 8:55AM<br />
Location: Room 207, Level 2, Washington Convention Center<br />
Presentation: Educational Session<br />
Weissman Research Interests: Our laboratory is looking at how cells ensure that proteins fold into their correct shape, as<br />
well as the role of protein misfolding in disease and normal physiology. We are developing experimental and analytical<br />
approaches for exploring the organizational principles of biological systems and globally monitoring protein translation<br />
through ribosome profiling. Additionally, our research focuses on identifying and understanding the machinery necessary<br />
for efficient folding, as well as studying the mechanism and consequences of protein misfolding. We are also developing<br />
experimental and analytical approaches for exploring the organizational principles of complex biological systems and for<br />
monitoring protein translation in vivo with unprecedented precision and depth.<br />
http://weissmanlab.ucsf.edu/research/research.html<br />
__________________________________________________________________________<br />
Brain cancer immunotherapy<br />
Authors*: Hideho Okada<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 10:15 - 12:15 PM<br />
Location: Independence Ballroom E-H, Meeting Level 4, Marriott Marquis DC<br />
Presentation: Educational Session<br />
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of<br />
novel immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune<br />
gene therapy trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic<br />
T-lymphocyte epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation<br />
antigen-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these<br />
findings to develop a number of vaccine trials in both adult and pediatric glioma patients. More recently, his group developed<br />
a novel chimeric antigen receptor targeting glioblastoma cells, and are currently conducting a pilot trial.<br />
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html<br />
6 *<strong>UCSF</strong> authors in bold
Presentations<br />
Tissue Tension: The extracellular martrix and PDAC phenotype<br />
Authors*: Valerie M. Weaver<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 11:15 - 11:40 AM<br />
Location: Room 151, Level 1, Washington Convention Center<br />
Presentation: Educational Session<br />
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences<br />
cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins,<br />
syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate<br />
cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and<br />
organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into<br />
two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor<br />
progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.<br />
http://weaverlab.ucsf.edu<br />
__________________________________________________________________________<br />
Transforming breast cancer treatment with CDK4/6 inhibitors<br />
Authors*: Hope S. Rugo<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 1:30 - 1:55 AM<br />
Location: Room 145, level 1, Washinton Convention Center<br />
Presentation: Educational Session<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials<br />
focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC).<br />
She also works on studies to improve supportive care for early & late stage BC patients, including with <strong>UCSF</strong>’s Advanced<br />
Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order<br />
to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education<br />
Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research<br />
Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the<br />
safety committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>, Dr. Rugo runs the Breast Forum, a bimonthly<br />
educational session for breast cancer patients, families & friends from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
7 *<strong>UCSF</strong> authors in bold
Presentations<br />
Translating the cancer genome one codon at a time and its therapeutic implications<br />
Authors*: Davide Ruggero<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 1:00 - 1:25 PM<br />
Location: Room 206, Level 2, Washington Convention Center<br />
Presentation: Educational Session<br />
__________________________________________________________________________<br />
Response to checkpoint therapy and exhausted CTL in the tumor microenvironment<br />
Authors*: Adil I. Daud<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 1:00 - 1:20 PM<br />
Location: Ballroom C, Level 3, Washington Convention Center<br />
Presentation: Methods Workshop<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and specifically<br />
understanding the biology of the immune response to PD-1 in melanoma. We developed IL- 12 gene therapy in melanoma<br />
and carried out the first in human clinical trial in 2005-2007. Based on this work, IL-12 electroporation is being explored in<br />
many cancers as an immune agent and as a combination treatment with PD-1 and other checkpoint inhibitors in melanoma.<br />
I have been involved in the development of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and<br />
Max Krummel at <strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets of melanoma (and<br />
potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
8 *<strong>UCSF</strong> authors in bold
Presentations<br />
A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma<br />
Authors*: Margaret A. Tempero<br />
Presentation #:<br />
Presentation Date/Time: April 1, 2017, 5:30 - 5:55 PM<br />
Location: Room 202, Level 2, Washington Convention Center<br />
Presentation: Special Session<br />
Tempero Research Interests: Director of the <strong>UCSF</strong> Pancreas Center and Leader of the <strong>UCSF</strong> Pancreas Cancer Program, Dr.<br />
Tempero oversees research projects from risk assessment to early detection, biology, and therapeutics in PNET and PDAC.<br />
Her personal research career has focused on the area of investigational therapeutics in PDAC. She was a pioneer in the use<br />
of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Dr. Tempero’s group developed<br />
effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival, and is currently<br />
assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. She is a DreamTeam<br />
P.I. on a SU2C grant evaluating innovative immunotherapy approaches, and is co-PI on a U01 award to establish high risk<br />
cohorts for testing early diagnosis biomarkers. She has served as the NCCN Guidelines Panel Chair on Pancreatic Cancer<br />
since 2000, and on several SABs including the Mayo Clinic Pancreas Cancer SPORE and MDACC’s Moon Shot Program.<br />
http://cancer.ucsf.edu/people/profiles/tempero_margaret.3701<br />
9 *<strong>UCSF</strong> authors in bold
Presentations<br />
Sunday, April 2, 2017<br />
Targeting BRD4 overcomes cetuximab resistance in HNSCC<br />
Authors*: Toni Brand, Yan Zeng, Brandon Leonard, Rachel O’ Keefe, Hua Li, Daniel Johnson,<br />
Jennifer Grandis, Neil E. Bhola<br />
Presentation #: 95<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 4<br />
Presentation: Poster Session/ Board #16<br />
Head and Neck Cancer Lab: is dedicated to increasing our understanding of head and neck squamous cell carcinoma<br />
(HNSCC) to develop new treatment and prevention approaches. One overarching theme is to identify predictive biomarkers that<br />
will identify which treatment(s) are most effective for individual patients, thus allowing for personalized medicine. Translational<br />
resources we have developed to support our projects include a large collection of patient-derived xenografts (PDXs)<br />
and tissue microarrays containing over 500 human HNSCC research samples linked to a professionally curated clinical and<br />
pathologic database that includes information on treatment and survival. In addition to basic and translational research,<br />
we also have experience conducting investigator-initiated clinical trials of novel therapeutics, including an antisense EGFR<br />
(epidermal growth factor receptor) gene therapy and a novel decoy oligonucleotide targeting STAT3 (signal transducer and<br />
activator of transcription).<br />
https://ohns.ucsf.edu/signaling-lab<br />
__________________________________________________________________________<br />
Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton<br />
and PI3K/Akt signaling pathways<br />
Authors*: Mitsuho Imai-Sumida, Takeshi Chiyomaru, Shahana Majid, Priyanka Kulkarni, Pritha Dasgupta, Sharanjot Saini,<br />
Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varahram Shahryari, Hannah Nip,<br />
Rajvir Dahiya, Yuichiro Tanaka, Soichiro Yamamura<br />
Presentation #: 199<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 8<br />
Presentation: Poster Session/ Board #28<br />
10 *<strong>UCSF</strong> authors in bold
Presentations<br />
Site specific risk factors for colorectal cancer<br />
Authors*: Samir Gupta, Ranier Bustamante, Ashley Earles, Maria E. Martinez, Karen Messer, Christina D. Williams,<br />
Andrew J. Gawron, Tonya Kaltenbach, Lin Liu<br />
Presentation #: 281<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 12<br />
Presentation: Poster Session/ Board #25<br />
Kaltenbach Research Interests: Dr. Kaltenbach is an active researcher and educator in the field of advanced endoscopic<br />
imaging and therapy. She has numerous publications on non-polypoid neoplasia, image enhanced endoscopy and<br />
endoscopic mucosal resection. She is currently leading a national intiative to measure and report colonoscopy quality<br />
across the VAs, and moreover, aims to improve colonoscopy quality through provider feedback and teaching. She played<br />
a major role in the recent efforts to enhance the quality of colonoscopy for the surveillance and management of dysplasia<br />
in inflammatory bowel disease throughout the world. These efforts have brought forward a practice paradigm that is<br />
built on evidence based medicine, and have included a new consensus guideline, atlas, teaching video and practice and<br />
implementation algorithm.<br />
http://profiles.ucsf.edu/tonya.kaltenbach<br />
__________________________________________________________________________<br />
Regulation of macropinocytosis-dependent cell survival in pancreatic cancer cells<br />
Authors*: Sung Eun Kim, Man-Tzu Wang, Frank McCormick<br />
Presentation #:435<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 18<br />
Presentation: Poster Session/ Board #16<br />
11 *<strong>UCSF</strong> authors in bold
Presentations<br />
The role of miR-24 as a race-related genetic factor in prostate cancer<br />
Authors*: Yutaka Hashimoto, Marisa Shiina, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid,<br />
Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Yozo Mitsui, Mitsuho Sumida, Guoren Deng,<br />
Laura Tabatabai, Deepak Kumar, Rajvir Dahiya<br />
Presentation #: 462<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 19<br />
Presentation: Poster Session/ Board #3<br />
Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/<strong>UCSF</strong> under the leadership<br />
of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have<br />
developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these<br />
diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and<br />
metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney<br />
tumor progression and metastasis.<br />
https://urology.ucsf.edu/people/rajvir-dahiya<br />
__________________________________________________________________________<br />
Differential expression of miR-34b and androgen receptor pathway regulate<br />
prostate cancer aggressiveness between African Americans and Caucasians<br />
Authors*: Marisa Shiina, Yutaka Hashimoto, Taku Kato, Soichiro Yamamura, Yuichiro Tanaka, Shahana Majid,<br />
Sharanjot Saini, Shahryari Varahram, Priyanka Kulkarni, Prita Dasgupta, Mitsuho Sumida, Guoren Deng, Rajvir Dahiya<br />
Presentation #: 483<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 19<br />
Presentation: Poster Session/ Board #24<br />
Dahiya Research Interests: My group, which is part of the Urology Research Center at the VAMC/<strong>UCSF</strong> under the leadership<br />
of Dr. Peter Caroll, focuses on mechanisms of growth control in GU disorders, especially prostate and renal cancer. We have<br />
developed various novel methods for evaluating epigenetic pathways, microRNAs, gene regulation, and function in these<br />
diseases both in in vitro and in vivo models. In particular we are studying the role of microRNAs in the progression and<br />
metastasis of prostate cancer, diet, miRNAs, epigenetic changes in prostate cancer and wnt antagonist genes in kidney<br />
tumor progression and metastasis.<br />
https://urology.ucsf.edu/people/rajvir-dahiya<br />
12 *<strong>UCSF</strong> authors in bold
Presentations<br />
Clustering analysis of next-generation sequencing T cell repertoire data in<br />
sipuleucel-T treated prostate cancer patients<br />
Authors*: Li Zhang, Sounak Chakraborty, Jason Cham, David Oh, Nadeem Sheikh, Lawrence Fong<br />
Presentation #: 549<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 23<br />
Presentation: Poster Session/ Board #10<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor<br />
immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor<br />
immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine<br />
how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders<br />
may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that<br />
are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
__________________________________________________________________________<br />
Mechanism of liver metastasis induced systemic suppression of checkpoint<br />
inhibitor response<br />
Authors*: James C. Lee, Adil Daud, Jeff Bluestone<br />
Presentation #: 683A<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 28<br />
Presentation: Poster Session/ Board #30<br />
Bluestone Research Interests: Our lab is broadly focused on understanding mechanisms regulating T cell activation. We<br />
have developed soluble receptor antagonists; mAbs & animals deficient in individual members of TCR & co-stimulatory<br />
pathways to define their individual roles in transplant rejection & autoimmunity including a special emphasis on regulatory<br />
T cells (Treg). We have also adapted animal studies to use biologics & cell-based therapies to develop therapeutics that can<br />
be used in humans with autoimmunity & under conditions of allotransplant rejection. A strong role for antigen-specific Tregs<br />
has been found in these model systems. Thus, the major goal of our work is to identify the antigen-specificity of thymic-<br />
& peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, our lab is<br />
determining mechanisms that control Treg stability with the goal of developing approaches using pharmacogenomics to<br />
either stabilize or destabilize Tregs in autoimmunity & cancer.<br />
http://bluestone.ucsf.edu<br />
13 *<strong>UCSF</strong> authors in bold
Presentations<br />
TGFβ controls the DNA damage response via miR-182 regulation of BRCA1 and ATM<br />
Authors*: Qi Liu, Haydeliz Martinez-Ruiz, John Murnane, Simon N. Powell, Mary Helen Barcellos-Hoff<br />
Presentation #: 831<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 39<br />
Presentation: Poster Session/ Board #9<br />
Barcellos-Hoff Research Interests: The Barcellos-Hoff lab has actively pursued the translational potential of TGFβ inhibition<br />
in the context of radiotherapy in human cancer based on preclinical studies in mouse brain, breast, and lung tumor models.<br />
TGFβ inhibitors increase radiation sensitivity (i.e., 10-70% less dose is needed to reduce survival by 90%), inhibit molecular<br />
recognition of DNA damage, compromise DNA repair, and increases tumor control by radiation. Although most cancers are<br />
resistant to TGFβ growth control, most cancer cells appear to require TGFβ to effectively execute the genotoxic stress program,<br />
which provides a novel avenue to improve therapeutic response.<br />
http://cancer.ucsf.edu/people/profiles/barcellos-hoff_mary.6915<br />
__________________________________________________________________________<br />
Asymmetric cell division regulator prevents hyperproliferation in glioma cell-of-origin<br />
Authors*: Mathieu Daynac, Claudia K. Petritsch<br />
Presentation #: 916<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 43<br />
Presentation: Poster Session/ Board #9<br />
Petritsch Research Interests: The Petritsch Lab uses pharmacological, molecular, and in vivo and ex vivo techniques,<br />
to uncover the mechanism for cell fate decisions in oligodendrocyte precursor cells, in the healthy and diseased brain.<br />
Oligodendrocytes arise from oligodendrocyte precursor cells (OPCs) and accomplish myelination in the central nervous<br />
system to regulate axonal function. Although OPCs are the most abundant proliferative population in the adult and ageing<br />
brain, little is known about the underlying molecular regulation of OPC functions. In our lab, we are examining whether OPCs<br />
in the adult central nervous system decide about their fate by undergoing asymmetric divisions, whether the underlying<br />
mechanism of asymmetric cell divisions in mammalian cells diverge from the process found in Drosophila neuroblasts,<br />
whether this divergence involves epigenetic regulators and is there a cell intrinsic or extrinsic mechanism that determines<br />
whether OPC divisions are symmetrical or asymmetrical.<br />
http://petritschlab.ucsf.edu<br />
14 *<strong>UCSF</strong> authors in bold
Presentations<br />
Oncology model fidelity scores<br />
Authors*: Debajyoti Datta, Theodore Goldstein, Zhiping Gu, Atul Butte<br />
Presentation #: LB-006<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 34<br />
Presentation: Poster Session/ Board #5<br />
Butte Research Interests: Dr. Butte’s group builds and applies tools that convert more than 400 trillion points of molecular,<br />
clinical, and epidemiological data into diagnostics, therapeutics, and new insights into disease. This research has led to truly<br />
novel insights into ways to treat diseases and the founding of three investor-backed data-driven companies. His lab uses the<br />
bioinformatics methods that they have developed in-house to integrate, leverage, and reason over genomic, genetic, phenotypic,<br />
and other sources of molecular data to yield tools for physicians and patients. Additionally, his lab has developed tools for<br />
indexing public genomic data sets, re-mapping microarray data and in cloud-computing, as well as novel methods to explore<br />
human physiology using electronic health record data and in the medical risk estimation from whole genomes.<br />
http://buttelab.ucsf.edu<br />
__________________________________________________________________________<br />
The Pediatric Brain Tumor Atlas: building an integrated, multi-platform data-rich<br />
ecosystem for collaborative discovery in the cloud<br />
Authors*: Adam C. Resnick, Phillip B. Storm, Angela J. Waanders, Jena V. Lilly, Rishi R. Lulla, Sabine Mueller, Michael Prados,<br />
Leonard S. Sender, Allison Heath, Alex S. Felmeister, Anthony Cros, Yuankun Zhu, Pichai Raman<br />
Presentation #: LB-008<br />
Presentation Date/Time: April 2, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 34<br />
Presentation: Poster Session/ Board #7<br />
Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium<br />
for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium of<br />
now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at <strong>UCSF</strong> devoting his<br />
efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric brain<br />
tumor SPORE project at <strong>UCSF</strong> and is co-Project Leader of the PNOC. His major interests are early phase clinical trials research<br />
and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial board<br />
of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain<br />
Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from<br />
the Society of Neuro-Oncology.<br />
http://cancer.ucsf.edu/people/profiles/prados_michael.3603<br />
15 *<strong>UCSF</strong> authors in bold
Presentations<br />
The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research<br />
Authors*: Frank McCormick, Frederick Streitz, Andrew Stephen, Frantz L. Jean-Francois, Thomas J. Turbyville -Invited Speakers<br />
Presentation #:<br />
Presentation Date/Time: April 2, 2017, 2:45 - 4:15 PM<br />
Location: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC<br />
Presentation: NIH Sponsored Section<br />
__________________________________________________________________________<br />
Meet the Research Icon: Bruce M. Alberts, PhD, Organized by the Associate<br />
Member Council (AMC)<br />
Authors*: Bruce M. Alberts<br />
Presentation #:<br />
Presentation Date/Time: April 2, 2017, 3:00 - 3:30 PM<br />
Location: AACR central Amphitheater (Booth 1125), Lower Level, Washington Convention Center<br />
Presentation: Meet the Research Icon<br />
16 *<strong>UCSF</strong> authors in bold
Presentations<br />
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition<br />
Authors*: Matthew J. Hangauer, Vasanthi S. Viswanathan, Matthew J. Ryan, Dhruv Bole, Jake Eaton, Stuart L. Schreiber,<br />
Frank McCormick, Michael T. McManus<br />
Presentation #: 1006<br />
Presentation Date/Time: April 2, 2017, 3:00 pm - 5:00 pm<br />
Location: Room 152, Level 1, Washington Convention Center<br />
Presentation: Minisymposium<br />
McManus Research Interests: The McManus lab studies fundamental processes relating to the regulation of gene expression.<br />
We take high-throughput approaches, analyzing hundreds of thousands to millions of experiments at once, using unique and<br />
complex libraries coupled to deep sequencing. Our systems span from cell culture to in vivo models, focusing on a broad<br />
array of disease relevant tissues. From cancer to diabetes, we develop novel technologies to help us better understand how<br />
genes are regulated and how they function in cells. We aim to uncover the dark matter of the genome, to help unravel the<br />
beautiful genomic complexity of pathways and how genes interact in development and disease.<br />
http://mcmanuslab.ucsf.edu<br />
__________________________________________________________________________<br />
Selective impairment of intratumoral regulatory T cells by targeting Ezh2<br />
enhances cancer immunity<br />
Authors*: David Q. Wang, Jason R. Quiros, Chien-Chun S. Pai, Lawrence H. Fong, Jeffrey A. Bluestone, Michel J. DuPage<br />
Presentation #: 1014<br />
Presentation Date/Time: April 2, 2017, 3:00 pm - 5:00 pm<br />
Location: Room 146, Level 1, Washington Convention Center<br />
Presentation: Minisymposium<br />
DuPage Research Interests: The DuPage lab is focused on examining the interface of the immune system and cancer.<br />
We aim to establish a new paradigm for augmenting immune responses against cancer by uncovering and subsequently<br />
targeting mechanisms that control T regulatory cell programming within the tumor microenvironment. We have identified<br />
key intracellular pathways, both signaling cascades and epigenetic enzymes, that when targeted, selectively reprogram<br />
intratumoral T regulatory cell function to enhance anti-cancer immunity. Our approach utilizes sophisticated genetic tools to<br />
modify T cells and tumor cells in a dynamic fashion during tumor progression and in the context of the most advanced preclinical<br />
cancer models of the human disease.<br />
http://profiles.ucsf.edu/michel.dupage<br />
17 *<strong>UCSF</strong> authors in bold
Presentations<br />
Monday, April 3, 2017<br />
Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat<br />
castration-resistant prostate cancer<br />
Authors*: Michael A. Moses, Yeong Sang Kim, Genesis Rivera-Marquez, Matthew J. Watson, Sunmin Lee, Andrea Kravats,<br />
Sue Wickner, Jason Gestwicki, Jane Trepel, Len Neckers<br />
Presentation #: 1180<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 5<br />
Presentation: Poster Session/ Board #25<br />
Gestwicki Research Interests: We are interested in how molecular chaperones, such as Hsp70 and Hsp90, work together to<br />
maintain protein homostasis, which is the balance of protein folding, trafficking and turnover. Understanding this delicate<br />
balance is important because protein homeostasis is dramatically disrupted in many diseases, especially neurodegeneration<br />
and cancer. Our approach is to create small molecules that disrupt (or promote) interactions between chaperones. Using these<br />
chemical probes, we perturb protein-protein interactions and learn how this chaperone network is “wired”. These studies have<br />
taken us into many exciting areas of biotechnology and chemical biology.<br />
http://gestwickilab.ucsf.edu<br />
__________________________________________________________________________<br />
FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK<br />
inhibitor combination<br />
Authors*: Victoria E. Wang, Jeffrey Settleman, Frank McCormick<br />
Presentation #: 1209<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 6<br />
Presentation: Poster Session/ Board #24<br />
18 *<strong>UCSF</strong> authors in bold
Presentations<br />
Pathway analysis of insulin-like growth factor candidate genes and risk of<br />
pediatric rhabdomyosarcoma<br />
Authors*: Libby Morimoto, XIaorong Shao, Anand Chokkalingam, Joseph Wiemels, Xiaomei Ma, Catherine Metayer<br />
Presentation #: 1273<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 11<br />
Presentation: Poster Session/ Board #4<br />
Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal<br />
tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and<br />
chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as<br />
potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco<br />
Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention.<br />
This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians,<br />
biologists, and statisticians.<br />
http://profiles.ucsf.edu/joe.wiemels<br />
__________________________________________________________________________<br />
Genetic reclassification of prostate-specific antigen levels for personalized<br />
prostate cancer screening<br />
Authors*: Rebecca E. Graff, Thomas J. Hoffmann, Michael N. Passarelli, Nima C. Emami, Lori C. Sakoda,<br />
Eric Jorgenson, Laurel A. Habel3, Jun Shan, Dilrini K. Ranatunga, Charles P. Quesenberry, Jr., Chun R. Chao4,<br />
Nirupa R. Ghai, David Aaronson, Joseph Presti, Tobias Nordström, Zhaoming Wang, Sonja I. Berndt, Stephen J. Chanock,<br />
Jonathan D. Mosley, Robert J. Klein, Mridu Middha, Hans Lilja, Olle Melander, Mark N. Kvale, Pui-Yan Kwok,<br />
Catherine Schaefer, Neil Risch, Stephen K. Van Den Eeden, John S. Witte<br />
Presentation #: 1297<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 11<br />
Presentation: Poster Session/ Board #28<br />
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic<br />
epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher &<br />
Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation<br />
sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth<br />
defects, and pharmacogenomics.<br />
http://wittelab.ucsf.edu/pages/research<br />
19 *<strong>UCSF</strong> authors in bold
Presentations<br />
Identification of pleiotropic cancer susceptibility variants from genome-wide<br />
association studies reveals functional characteristics<br />
Authors*: Yi-Hsuan Wu, Rebecca E. Graff, Michael N. Passarelli, Thomas J. Hoffmann, Elad Ziv, John S. Witte<br />
Presentation #:1310<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 12<br />
Presentation: Poster Session/ Board #11<br />
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic<br />
epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher &<br />
Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation<br />
sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth<br />
defects, and pharmacogenomics.<br />
http://wittelab.ucsf.edu/pages/research<br />
__________________________________________________________________________<br />
Germline genetic signals across multiple aggressive prostate cancer phenotypes<br />
Authors*: Caroline G. Tai, Nima C. Emami, Thomas J. Hoffmann, Lori C. Sakoda, Eric Jorgenson, Laurel A. Habel, Jun Shan,<br />
Dilrini K. Ranatunga, Chun R. Chao, Nirupa R. Ghai, David Aaronson, Joseph Presti, Catherine Schaefer, Neil Risch,<br />
Stephen K. Van Den Eeden, John S. Witte<br />
Presentation #:1316<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 12<br />
Presentation: Poster Session/ Board #17<br />
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic<br />
epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher &<br />
Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation<br />
sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth<br />
defects, and pharmacogenomics.<br />
http://wittelab.ucsf.edu/pages/research<br />
20 *<strong>UCSF</strong> authors in bold
Presentations<br />
Non-additive and interaction effects of HLA class 2 polymorphism contributing to<br />
risk of glioma<br />
Authors*: Chenan Zhang, Kyle Walsh<br />
Presentation #: 1320<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 12<br />
Presentation: Poster Session/ Board #21<br />
Walsh Research Interests: Dr. Walsh’s research program is divided into two components: genetic epidemiology and functional<br />
genomics. The epidemiology component focuses on the use of genomic data from large population-based cohorts to<br />
identify the causes of cancer. This computational work stresses statistical methodologies for “gene hunting”, including<br />
GWAS, fine-mapping, admixture mapping, and whole-genome sequencing. This ongoing work has identified novel risk<br />
factors for glioma and childhood leukemia. The functional genomics component investigates the biological impact of genetic<br />
variants linked to cancer risk. Dr. Walsh’s laboratory utilizes numerous techniques, including: digital droplet PCR, ChIP,<br />
FISH, and luciferase reporter assays. Special focus is given to the interface of the inherited genome and the tumor genome.<br />
Deregulation of tumor suppression mechanisms, such as telomere-induced cell senescence, is of particular interest.<br />
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_walsh<br />
__________________________________________________________________________<br />
Variable drug responses characterize the functional heterogeneity of Nf1 null tumors<br />
Authors*: Daniela Pucciarelli, Ganesh Krishnamurthi, Steve Braunstein, Jean L. Nakamura<br />
Presentation #: 1356<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 14<br />
Presentation: Poster Session/ Board #7<br />
Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can<br />
lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers<br />
in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an<br />
experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using<br />
this information to develop better therapies. A second area of research is trying to understand why second cancers develop<br />
in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom<br />
are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we<br />
expect to understand the biological processes leading to second cancers, and one day prevent these complications.<br />
https://radonc.ucsf.edu/jean-nakamura<br />
21 *<strong>UCSF</strong> authors in bold
Presentations<br />
Structural basis of impaired GTP hydrolysis in oncogenic mutants of KRAS<br />
Authors*: Timothy Tran, Sathiya Dharmaiah, Oleg Chertov, Timothy Waybright, William Gillette, Dominic Esposito,<br />
Dwight Nissley, Frank McCormick, Andrew Stephen, Dhirendra Simanshu<br />
Presentation #: 1366<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 14<br />
Presentation: Poster Session/ Board #17<br />
__________________________________________________________________________<br />
EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive<br />
Ras/MAPK signaling<br />
Authors*: Evan Markegard, Ellen L. Mercado, Jillian M. Silva, Jacqueline Galeas, Marena I. Trinidad, Anatoly Urisman,<br />
Frank McCormick<br />
Presentation #: 1370<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 14<br />
Presentation: Poster Session/ Board #21<br />
22 *<strong>UCSF</strong> authors in bold
Presentations<br />
Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF)<br />
treatment increases T cell receptor diversity in localized and metastatic<br />
prostate cancer patients<br />
Authors*: David Y. Oh, Li Zhang, Jason Cham, Alan Paciorek, Mark Klinger, Malek Faham, Susan F. Slovin, Lawrence Fong<br />
Presentation #: 1694<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 29<br />
Presentation: Poster Session/ Board #13<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor<br />
immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor<br />
immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine<br />
how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders<br />
may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that<br />
are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
__________________________________________________________________________<br />
Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous<br />
cell carcinoma<br />
Authors*: Matthew Louis Hedberg, Noah Peyser, William Gooding, Hua Li, Toni Brand, Victor Olivas, Trever Bivona,<br />
Simion Choisea, Lin Wang, Jonas Johnson, Uma Duvvuri, Robert Ferris, Daniel Johnson, Patrick Ha, Julie Bauman,<br />
Jennifer Grandis<br />
Presentation #: 1779<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 32<br />
Presentation: Poster Session/ Board #9<br />
Grandis Research Interests: The Grandis lab has played a major role in determining the mutational landscape of head<br />
and neck squamous cell carcinoma (HNSCC) and is focused on determining the role of frequently mutated genes in this<br />
malignancy. PIK3CA is the most commonly altered is the most commonly altered oncogene in HNSCC. Prior work in colon<br />
cancer has suggested an association between regular aspirin use and extended survival in patients with PIK3CA mutations.<br />
Using a large cohort of patients with HNSCC, the Grandis lab has determined that chronic NSAID use is associated with<br />
dramatically improved survival in patients with altered PIK3CA. They have characterized the mechanism of action of PIK3CA<br />
mutations and the impact of NSAIDs on these mechanistic pathways. Further, they plan a large prospective clinical trial that<br />
will directly assess the therapeutic benefit of NSAIDs in HNSCC patients with specific mutational profiles.<br />
http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048<br />
23 *<strong>UCSF</strong> authors in bold
Presentations<br />
Tumor-specific copy number alterations uncover therapeutic opportunities<br />
in osteosarcoma<br />
Authors*: Leanne C. Sayles, Marcus Breese, Amanda L. Koehne, Stanley Leung, Aviv Spillinger, Alex Lee, Avanthi Shah,<br />
Krystal Straessler, Sheri Spunt, Neyssa Marina, Damon Jacobson, Raffi S. Avedian, David G. Mohler, Steven DuBois,<br />
Douglas S. Hawkins, E. Alejandro Sweet-Cordero<br />
Presentation #: 1948<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 42<br />
Presentation: Poster Session/ Board #20<br />
Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic<br />
mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and<br />
human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that<br />
regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy.<br />
We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of<br />
chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role<br />
for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in<br />
NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work,<br />
we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.<br />
https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106<br />
__________________________________________________________________________<br />
STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with<br />
advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or<br />
ALK fusions<br />
Authors*: Ami V. Desai, Garrett M. Brodeur, Jennifer Foster, Suzanne Shusterman, Amit J. Sabnis, Magaret Macy,<br />
Cynthia Wetmore, Ellen Basu, Zachary Hornby, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox<br />
Presentation #: CT030<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 33<br />
Presentation: Poster Session/ Board #6<br />
Sabnis Research Interests: Dr. Sabnis’s research uses patient-derived models to identify and pre-clinically validate new<br />
therapies for high-risk pediatric sarcomas. In work with his mentor, Dr. Trever Bivona, and other collaborators at <strong>UCSF</strong>, he has<br />
developed a nascent program focusing on targets within protein homeostasis networks. In addition, he sees patients within the<br />
Early Phase Clinical Trials group of the <strong>UCSF</strong> Benioff Children’s Hospital Division of Pediatric Hematology-Oncology.<br />
http://cancer.ucsf.edu/people/profiles/sabnis_amit.7897<br />
24 *<strong>UCSF</strong> authors in bold
Presentations<br />
A phase Ib trial to study the safety and tolerability of atezolizumab with<br />
radium-223 dichloride in patients with metastatic castrate-resistant prostate<br />
cancer (mCRPC)<br />
Authors*: Lawrence Fong, Michael Morris, Andrew Armstrong, Daniel Petrylak, Ulka Vaishampayan, Ajjai Alva,<br />
Jean Hoffman-Censits, Indrani Sarkar, Susheela Carroll, Christina Schiff, Oliver Sartor<br />
Presentation #: CT031<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 33<br />
Presentation: Poster Session/ Board #7<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor<br />
immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor<br />
immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine<br />
how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders<br />
may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that<br />
are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
__________________________________________________________________________<br />
Copy number estimation from targeted amplicon-based next-generation<br />
sequencing of castration-resistant prostate cancer biopsies: analytic validation<br />
and clinical qualification for a iPARP clinical trial<br />
Authors*: George Seed, Wei Yuan, Joaquin Mateo, Suzanne Carreira, Maryou Lambros, Gunther Boysen, Roberta Ferraldeschi,<br />
Susana Miranda, Ines Figueiredo, Ruth Riisnaes, Mateus Crespo, Daniel Nava Rodrigues, Eric Talevich, Dan Robinson,<br />
Priya Kunju, Yi-mi Wu, Robert Lonigro, Shahneen Sandhu, Arul Chinnayan, Johann De Bono<br />
Presentation #: LB-044<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 34<br />
Presentation: Poster Session/ Board #6<br />
Talevich Research Interests: Dr. Talevich is a bioinformatician in the Clinical Cancer Genomics Laboratory (CCGL) at the<br />
<strong>UCSF</strong> Medical center, supporting clinical care and translational research efforts in precision medicine, including the <strong>UCSF</strong><br />
500 cancer gene panel service. His area of focus is the design and construction of genomic analysis pipelines to support<br />
short-read (Illumina) DNA and RNA sequencing of cancer samples for patient care, and the development of software and<br />
databases for sample tracking, quality control, genome characterization and mutation calling, and functional annotation to<br />
facilitate clinical review.<br />
http://profiles.ucsf.edu/eric.talevich<br />
25 *<strong>UCSF</strong> authors in bold
Presentations<br />
PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity<br />
Authors*: Matthew J. Schiewer, Amy C. Mandigo, Nicolas Gordon, Fangjin Huang, Sanchaika Gaur, Shuang Zhao, Joseph Evans,<br />
Sumin Han, Theodore Parsons, Ruth Birbe, Peter McCue, Tapio Visakorpi, Ganesh Raj, Mark Rubin, Johann de Bono,<br />
Costas Lallas, Edouard Trabulsi, Leonard G. Gomella, Adam P. Dicker, Kevin Kelly, Beatrice Knudsen, Felix Feng,<br />
Karen E. Knudsen<br />
Presentation #: LB-086<br />
Presentation Date/Time: April 3, 2017, 8:00 am - 12:00 noon<br />
Location: Section 36<br />
Presentation: Poster Session/ Board #11<br />
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s<br />
research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment<br />
resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological<br />
perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular<br />
biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive<br />
disease progression, and 3) to develop therapeutic approaches to target these disease drivers.<br />
https://radonc.ucsf.edu/felix-feng<br />
__________________________________________________________________________<br />
Forcing tumor progression and aggression<br />
Authors*: Valerie M Weaver<br />
Presentation #:<br />
Presentation Date/Time: April 3, 2017, 11:20 - 11:40 AM<br />
Location: Room 202, Level 2, Washington Convention Center<br />
Presentation: Major Symposium<br />
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences<br />
cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins,<br />
syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate<br />
cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and<br />
organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into<br />
two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor<br />
progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.<br />
http://weaverlab.ucsf.edu<br />
26 *<strong>UCSF</strong> authors in bold
Presentations<br />
Landscape analysis of the initial data release from AACR Project GENIE<br />
Authors*: Ethan Cerami, Alexander S. Baras, Justin Guinney, Eva Lepisto, Trevor J. Pugh, Nikolaus Schultz, Thomas Stricker,<br />
Shawn M. Sweeney, Laura J. van’t Veer, Gerrit A. Meijer, Fabrice Andre, Victor E. Velculescu, Kenna R. Shaw, Mia A. Levy,<br />
Philippe L. Bedard, Barrett J. Rollins, Charles L. Sawyers<br />
Presentation #: LB-102<br />
Presentation Date/Time: April 3, 2017, 11:55 - 12:05 PM<br />
Location: Ballroom A-B, Level 3, Washington Convention Center<br />
Presentation: Major Symposium<br />
van’t Veer Research Interests: Dr. van ’t Veer’s research focuses on personalized medicine & advancing patient management<br />
based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. Her laboratory<br />
investigates human kinases & how kinase inhibitors elicit response & resistance, which is also utilized to understand agent<br />
efficacy in the I-SPY 2 TRIAL. She is the PI of the Athena Breast Health Network, a 150,000 women cohort study evaluating<br />
new paradigms to enhance breast health. She leads the targeted genome testing of 100,000 women for 9 breast cancer<br />
susceptibility genes and a selection of ~100 known susceptibility SNPs. She is one of the PIs for the NIH Big Data to<br />
Knowledge Center Translational Genomics, facilitating worldwide standardization of sharing annotated genomics data.<br />
http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358<br />
__________________________________________________________________________<br />
MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib,<br />
a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast<br />
cancer, after chemotherapy for advanced disease<br />
Authors*: Hope S. Rugo, Sara M. Tolaney, Javier Cortés, Véronique Diéras, Debra A. Patt, Hans Wildiers, Shivani Nanda,<br />
Andrew G. Koustenis, Maura N. Dickler, José Baselga<br />
Presentation #: CT044<br />
Presentation Date/Time: April 3, 2017, 10:35 - 10:55 AM<br />
Location: Ballroom C, Level 3, Washington Convention Center<br />
Presentation: Clinical Trials Plenary Session<br />
Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials<br />
focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC).<br />
She also works on studies to improve supportive care for early & late stage BC patients, including with <strong>UCSF</strong>’s Advanced<br />
Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order<br />
to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education<br />
Committee meeting, is a member of the Alliance & is a founding member of the translational Breast Cancer Research<br />
Consortium where she co-leads the triple negative working group. She is on the novel agents committee and leads the<br />
safety committee for the neoadjuvant multi-center I SPY2 trial. At <strong>UCSF</strong>, Dr. Rugo runs the Breast Forum, a bimonthly<br />
educational session for breast cancer patients, families & friends from throughout the bay area.<br />
http://cancer.ucsf.edu/people/profiles/rugo_hope.3648<br />
27 *<strong>UCSF</strong> authors in bold
Presentations<br />
Mechanisms of residual disease during targeted therapy<br />
Authors*: Trever G. Bivona<br />
Presentation #:<br />
Presentation Date/Time: April 3, 2017, 1:35 - 2:00 PM<br />
Location: Room 152, Level 1, Washington Convention Center<br />
Presentation: Major Symposium<br />
Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted<br />
therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing<br />
the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel<br />
potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers<br />
using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular<br />
pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale<br />
for novel clinical trials we are launching to improve patient survival.<br />
http://www.bivonalab.net/<br />
__________________________________________________________________________<br />
Neonatal hormone levels and risk of testicular germ cell tumors (TGCT)<br />
Authors*: Libby Morimoto, David Zava, Katherine McGlynn, Frank Stanczyk, Joseph Wiemels, Xiaomei Ma, Catherine Metayer<br />
Presentation #: 2263<br />
Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 11<br />
Presentation: Poster Session/ Board #17<br />
Wiemels Research Interests: The causes of most human cancers are unclear, but appear to be related to miscues in normal<br />
tissue developmental pathways, mutations (genetic and epigenetic) in critical genes caused by errors, infection, and<br />
chemicals, and a failure of recognition and removal of tumors by the immune system. Dr. Wiemels studies these factors as<br />
potential causes of hematopoietic and brain tumors. Large population-based studies of human cancer in the San Francisco<br />
Bay Area and State of California form a basis for examining the origin of these cancers, with a focus on future prevention.<br />
This type of research is highly collaborative, and Dr. Wiemels works with several epidemiologists, geneticists, clinicians,<br />
biologists, and statisticians.<br />
http://profiles.ucsf.edu/joe.wiemels<br />
28 *<strong>UCSF</strong> authors in bold
Presentations<br />
Effects of tobacco smoking and alcohol consumption on risks of CYP1B1<br />
polymorphisms for prostate cancer<br />
Authors*: Taku Kato, Yutaka Hashimoto, Shigekatsu Maekawa, Marisa Shiina, Mitsuho Imai-Sumida, Pritha Dasgupta,<br />
Priyanka Kulkarni, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Sharryari, Guoren Deng, Rajvir Dahiya,<br />
Yuichiro Tanaka<br />
Presentation #: 2288<br />
Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 12<br />
Presentation: Poster Session/ Board #12<br />
Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has<br />
involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling<br />
pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens,<br />
assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and<br />
determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The<br />
cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can<br />
lead to biomarkers as well as potential therapeutic implications for urological cancers.<br />
https://www.ncire.org/research/researchers_by_name/Yuichiro-Tanaka-PhD/<br />
__________________________________________________________________________<br />
The long noncoding RNA SChLAP1 inhibits the SWI/SNF complex, revealing a<br />
therapeutic opportunity in prostate cancer<br />
Authors*: Julia Dancourt, Anirban Sahu, John R. Prensner, Benjamin Chandler, Qi Cao, Nithin Edara, Udit Singhal,<br />
Matthew K. Lyer2, Rohit Malik, Xuhong Cao, Saravana M. Dhanasekaran, Yashar S. Niknafs, Shuang Zhao, Corey Speers,<br />
Arul M. Chinnaiyan, Felix Y. Feng<br />
Presentation #: 2546<br />
Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 21<br />
Presentation: Poster Session/ Board #25<br />
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s<br />
research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment<br />
resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological<br />
perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular<br />
biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive<br />
disease progression, and 3) to develop therapeutic approaches to target these disease drivers.<br />
https://radonc.ucsf.edu/felix-feng<br />
29 *<strong>UCSF</strong> authors in bold
Presentations<br />
Preclinical efficacy of daratumumab in acute lymphoblastic leukemia<br />
Authors*: Karen Lee Bride, Tiffaney Vincent, Soo-Yeon L. Im, Tori Fuller, Theresa Ryan, David M. Barrett, Shannon L. Maude,<br />
Mignon L. Loh, Michelle L. Hermiston, Stephan A. Grupp, Brent L. Wood, David T. Teachey<br />
Presentation #: 2642<br />
Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 26<br />
Presentation: Poster Session/ Board #1<br />
Loh Research Interests: The Loh lab has focused on translating genomic and biochemical discoveries in juvenile myelomonocytic<br />
(JMML) and acute lymphoblastic leukemia (ALL) into assays and therapies that can be incorporated into clinical trials. Their<br />
work in JMML has largely focused on dissecting the genomic landscape of JMML, including descriptions of PTPN11 and CBL<br />
mutations and the discovery of CBL as a new familial tumor suppressor gene. From these discoveries, Dr. Loh established<br />
JMML CLIA molecular diagnostic testing, which is now utilized as standard testing for patients suspected of having JMML.<br />
Dr. Loh is currently Chair of the Children’s Oncology Group (COG) ALL committee starting in April 2015 and responsible for<br />
supervising and implementing the next generation of national ALL trials for children, adolescents, and young adults.<br />
http://cancer.ucsf.edu/people/profiles/loh_mignon.3407<br />
__________________________________________________________________________<br />
STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients<br />
with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK<br />
gene fusions<br />
Authors*: Alexander Drilon, Kamalesh Kumar Sankhala, Stephen V. Liu, Byoung Chul Cho, Collin Blakely, Cheng E. Chee,<br />
Marwan Fakih, Jonathan Polikoff, Zachary Hornby, Lisa Schechet, David Luo, Edna Chow Maneval, Pratik S. Multani,<br />
Robert C. Doebele<br />
Presentation #: CT060<br />
Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 33<br />
Presentation: Poster Session/ Board #10<br />
Blakely Research Interests: The primary focus of my research is to translate laboratory-based findings into novel investigator<br />
sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients.<br />
My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling<br />
levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict<br />
TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that<br />
can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified<br />
oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX)<br />
mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies<br />
in lung cancer<br />
http://top.ucsf.edu/meet-the-team/medical-oncologists/collin-blakely,-md,-phd.aspx<br />
30 *<strong>UCSF</strong> authors in bold
Presentations<br />
COP1 E3 ligase modulates response to oncogenic MAPK pathway<br />
Authors*: Manasi K. Mayekar, Trever Bivona<br />
Presentation #: LB-124<br />
Presentation Date/Time: April 3, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 35<br />
Presentation: Poster Session/ Board #10<br />
Bivona Research Interests: Our team uses the tools of precision medicine to improve the molecular diagnosis and targeted<br />
therapy of patients with solid cancers, including lung cancer. Our program focuses on identifying and functionally characterizing<br />
the molecular drivers of tumor growth in individual patients. We study patient samples and clinical data to identify novel<br />
potential drivers of tumor initiation, progression, and therapy resistance. We functionally annotate the putative molecular drivers<br />
using an integrated approach of genetic and pharmacologic tools. This precision approach to understanding the molecular<br />
pathogenesis of lung cancer (and other cancers) has led to the discovery of new biomarkers and targets that provide rationale<br />
for novel clinical trials we are launching to improve patient survival.<br />
http://www.bivonalab.net/<br />
31 *<strong>UCSF</strong> authors in bold
Presentations<br />
Tuesday, April 4, 2017<br />
Characterizing tumor-adjacent normal tissue: Is it really normal?<br />
Authors*: Dvir Aran<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 7:00 - 8:00 AM<br />
Location: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC<br />
Presentation: NIH Sponsored Session<br />
Butte Research Interests: Dr. Butte’s group builds and applies tools that convert more than 400 trillion points of molecular,<br />
clinical, and epidemiological data into diagnostics, therapeutics, and new insights into disease. This research has led to<br />
truly novel insights into ways to treat diseases and the founding of three investor-backed data-driven companies. His lab<br />
uses the bioinformatics methods that they have developed in-house to integrate, leverage, and reason over genomic, genetic,<br />
phenotypic, and other sources of molecular data to yield tools for physicians and patients. Additionally, his lab has developed<br />
tools for indexing public genomic data sets, re-mapping microarray data and in cloud-computing, as well as novel methods to<br />
explore human physiology using electronic health record data and in the medical risk estimation from whole genomes.<br />
http://buttelab.ucsf.edu<br />
__________________________________________________________________________<br />
Cytoskeletal modulation results in increased tumor survival and drug resistance<br />
through attenuation of p53 dependent apoptosis<br />
Authors*: Victoria E. Wang, John Doench, David Root, Rene Bernards, Jeffrey Settleman, Frank McCormick<br />
Presentation #: 3182<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 7<br />
Presentation: Poster Session/ Board #13<br />
32 *<strong>UCSF</strong> authors in bold
Presentations<br />
Genistein inhibits renal cancer progression through long non-coding<br />
RNA HOTAIR suppression<br />
Authors*: Mitsuho Imai-Sumida, Shahana Majid, Pritha Dasgupta, Priyanka Kulkarni, Sharanjot Saini, Divya Bhagirath,<br />
Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Guoren Deng, Varahram Shahryari, Yuichiro Tanaka,<br />
Rajvir Dahiya, Soichiro Yamamura<br />
Presentation #: 3449<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 18<br />
Presentation: Poster Session/ Board #29<br />
__________________________________________________________________________<br />
LncRNA as potential target in drug-resistant melanomas<br />
Authors*: Rosaura Esteve-Puig, Martina Sanlorenzo, Igor Vujic, Kevin Lai1,Marin Vujic, Dallas Mould, Kevin Lin,<br />
Juan Oses-Prieto, Shreya Chand, Christian Posch, Alma Burlingame, Susana Ortiz-Urda<br />
Presentation #: 3493<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 20<br />
Presentation: Poster Session/ Board #16<br />
Ortiz-Urda Research Interests: The Ortiz lab is interested in the study of the functions of promoter and intronic sequences of<br />
melanoma related genes. Our lab studies the mechanisms of cancer progression and the resistance mechanisms to drugs.<br />
In addition, Ortiz’s lab uses novel nanotechnology approaches to detect mutations and to deliver specific drugs to the cells<br />
of interest. To study cancer progression, the Ortiz lab uses epithelial tissue and organotypic constructs as a model system.<br />
The latter encompass human skin regenerated on immune-deficient mice. Grafts can express different combination of genes<br />
allowing this the elucidation of factors that stimulate tumor progression. Furthermore, the Ortiz lab uses laser micro-dissection<br />
to study single cell genetics. In order to elucidate mechanisms of resistance to targeted therapeutics the Ortiz lab analyzes<br />
resistance melanoma cell lines at the level of genome and transcriptome.<br />
http://cancer.ucsf.edu/research/ortiz-lab<br />
33 *<strong>UCSF</strong> authors in bold
Presentations<br />
Splice expression variation analysis (SEVA) for differential gene isoform usage<br />
in cancer<br />
Authors*: Bahman Afsari, Theresa Guo, Michael Considine, Dylan Kelley, Emily Flam, Liliana Florea, Patrick Ha,<br />
Donald Geman, Michael F. Ochs, Joseph A. Califano, Daria A. Gaykalova, Alexander V. Favorov, Elana J. Fertig<br />
Presentation #: 3577<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 23<br />
Presentation: Poster Session/ Board #13<br />
Ha Research Interests: Dr. Ha’s lab interests align with his clinical practice of managing patients with complex head and neck<br />
cancers. He has had multiple NIH grants examining the molecular underpinnings of salivary gland adenoid cystic carcinoma<br />
in order to learn more about this rare but deadly disease. He serves on the editorial board of several journals including Head<br />
and Neck and Oral Oncology, and is now serving as the Chief of Head and Neck Surgical Oncology at the University of<br />
California San Francisco.<br />
http://ohns.ucsf.edu/patrick-ha<br />
__________________________________________________________________________<br />
Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional<br />
states of the cancer immunologic milieu<br />
Authors*: Noemi Andor, Erin Simonds, Jiamin Chen, Christina Wood, Susan Grimes, Debra Czerwinski, Grace Zheng,<br />
Ronald Levy, Hanlee P. Ji<br />
Presentation #: 3693<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 28<br />
Presentation: Poster Session/ Board #6<br />
Simonds Research Interests: I apply single-cell analysis techniques to understand how phenotypic heterogeneity contributes<br />
to cancer growth and resistance to therapy. I helped develop single-cell assays to study signaling in the healthy immune<br />
system, and in childhood leukemias and I am applying these same approaches to investigate phenotypic plasticity and<br />
immune infiltration in glioblastoma, the most common and lethal brain tumor. Many of my experiments are enabled by a<br />
next-generation flow cytometry platform (CyTOF mass cytometry), which can measure up to 42 protein expression and<br />
intracellular signaling markers at the single-cell level in millions of cancer cells. This platform provides detailed biochemical<br />
profiles of rare and complex samples, uncovering subpopulations that would have been overlooked by classical bulk protein<br />
and genetic assays.<br />
http://profiles.ucsf.edu/erin.simonds#narrative<br />
34 *<strong>UCSF</strong> authors in bold
Presentations<br />
Identification of a novel and a shared H3.3K27M mutation derived neoantigen<br />
epitope and H3.3K27M specific TCR engineered T cell therapy for glioma<br />
Authors*: Zinal Chheda, Gary Kohanbash, John Sidney, Kaori Okada, Naznin Jahan, Diego Carrera, Payal Watchmaker,<br />
Kira Downey, Shuming Liu, Shruti Shrivastav, Sabine Mueller, Ian F. Pollack, Angel M. Carcaboso, Alessandro Sette,<br />
Yafei Hou, Hideho Okada<br />
Presentation #: 3767<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 30<br />
Presentation: Poster Session/ Board #23<br />
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel<br />
immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy<br />
trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte<br />
epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine<br />
CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of<br />
vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor<br />
targeting glioblastoma cells, and are currently conducting a pilot trial.<br />
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html<br />
__________________________________________________________________________<br />
A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit<br />
lowered H3K27me3 and DNA hypomethylation and show epigenetic similarities<br />
with H3K27M mutant diffuse intrinsic pontine gliomas<br />
Authors*: Sriram Venneti, Jill Bayliss, Piali Mukherjee, Chao Lu, Siddhant Jain, Chan Chung, Daniel Martinez, Benjamin Sabari,<br />
Ashley Margol, Pooja Panwalkar, Abhijit Paroloia, Melike Pekmezci, Richard Mc Eachin, Marcin Cieslik, Benita Tamrazi,<br />
Benjamin Garcia, Gaspare La Rocca, Mariarita Santi, Peter Lewis, Cynthia Hawkins, Ari Melnick, C. David Allis, Craig B. Thompson,<br />
Arul Chinnaiyan, Alexander R. Judkins<br />
Presentation #: 3863<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 38<br />
Presentation: Poster Session/ Board #1<br />
Pekmezci Research Interests: Dr. Pekmezci is a clinical Neuropathologist and Ophthalmic Pathologist, who is involved in<br />
translational research with specific focus on diagnostic and prognostic markers of CNS neoplasms. She has been particularly<br />
interested in molecular classification and grading schemes of diffuse gliomas. In addition, her ongoing research includes<br />
diagnostic and prognostic markers of ocular surface neoplasms and uveal melanomas.<br />
https://www.pathology.ucsf.edu/about/faculty/pathology-mpekmezci.html<br />
35 *<strong>UCSF</strong> authors in bold
Presentations<br />
A novel combination therapy targeting BCL6 and phospho-STAT3 defeats<br />
intratumor heterogeneity in a subset of non-small cell lung cancers<br />
Authors*: Dhruba Deb, Satwik Rajaram, Jill E. Larsen, Patrick P. Dospoy, Rossella Marullo, Longshan Li, Kimberley Avila,<br />
Leandro Cerchietti, John D. Minna1, Lani F. Wu, Steven J. Altschuler<br />
Presentation #: 3950<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 41<br />
Presentation: Poster Session/ Board #17<br />
Altschuler and Wu Lab Research Interests: Over the past decade, our labs pioneered approaches for scalable, microscopybased<br />
drug discovery. We also pioneered experimental, computational and theoretical approaches for identifying functional<br />
roles in patterns of cellular heterogeneity. We showed that patterns of cell-cell differences can reveal hidden biological<br />
information about how cells make decisions and serve as an informative readout of disease progression and drug response.<br />
Methodologies developed in our labs have been widely adapted in academics and industry.<br />
http://cancer.ucsf.edu/people/profiles/altschuler_steven.5588<br />
__________________________________________________________________________<br />
NCoR2 regulates glioblastoma progression and treatment resistance<br />
Authors*: Shelly Kaushik, Joanna J. Phillips, Valerie M. Weaver<br />
Presentation #: 3985<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 42<br />
Presentation: Poster Session/ Board #28<br />
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences<br />
cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins,<br />
syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate<br />
cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and<br />
organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into<br />
two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor<br />
progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.<br />
http://weaverlab.ucsf.edu<br />
36 *<strong>UCSF</strong> authors in bold
Presentations<br />
Ribociclib + endocrine therapy (ET) doublet combinations in hormone<br />
receptor-positive (HR+), human epidermal growth factor receptor 2-negative<br />
(HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of<br />
molecular alterations<br />
Authors*: Dejan Juric, Mario Campone, Pamela Munster, Roohi Ismail-Khan, Laura Garcia Estévez, Mariana Chavez-MacGregor,<br />
Antonio Frassoldati, Rina Hui, Ingrid A. Mayer, Javier Cortés, Anthony Gonçalves, Richard H. De Boer, Luc Dirix, Sara M. Tolaney,<br />
Soo Chin Lee, Michela Maur, Yingbo Wang, Faye Su, Jason R. Dobson, Caroline Germa, Becker Hewes, Aditya Bardia<br />
Presentation #: CT087<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 33<br />
Presentation: Poster Session/ Board #5<br />
Munster Research Interests: Our lab is interested in developing novel strategies to overcome hormone therapy resistance in<br />
breast cancer.<br />
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449<br />
__________________________________________________________________________<br />
Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist,<br />
administered intratumorally in subjects with solid tumors<br />
Authors*: Shilpa Gupta, Juneko Grilley-Olson, David Hong, Aurélien Marabelle, Pamela Munster, Rahul Aggarwal,<br />
Sandrine Aspeslagh, Robert G. Dixon, Manish Patel, Vivek Subbiah, Chris Morehouse, Yuling Wu, Jiping Zha, Leo Tseng,<br />
Zachary A. Cooper, Shannon Morris, Joshua Brody<br />
Presentation #: CT091<br />
Presentation Date/Time: April 4, 2017, 8:00 am - 12:00 noon<br />
Location: Section 33<br />
Presentation: Poster Session/ Board #9<br />
37 *<strong>UCSF</strong> authors in bold
Presentations<br />
Precision medicine lessons from window-of-opportunity trials<br />
Authors*: Jennifer Rubin Grandis<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 9:15 - 9:45 AM<br />
Location: Hall D-E, Level 2, Washington Convention Center<br />
Presentation: Plenary Session<br />
__________________________________________________________________________<br />
Post-radiation mutational signatures<br />
Authors*: Jean L. Nakamura<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 12:04 - 12:30 PM<br />
Location: East Salon C, Level 1, Washington Convention Center<br />
Presentation: Special Session<br />
Nakamura Research Interests: The first area we study is Neurofibromatosis I (NF1), which is a genetic syndrome that can<br />
lead to tumors in children. Individuals with NF1 can develop brain tumors and tumors along their spines (as well as cancers<br />
in other organs). This is an incurable disease that can lead to many complications and even death. We have developed an<br />
experimental systems to study how mutations causing this disease actually lead to tumor formation, with the goal of using<br />
this information to develop better therapies. A second area of research is trying to understand why second cancers develop<br />
in some childhood cancer survivors. We analyze these second cancers from childhood cancer survivors (some of whom<br />
are now adults) for problems in the genetic code. By studying the abnormalities in the genetic code of second cancers, we<br />
expect to understand the biological processes leading to second cancers, and one day prevent these complications.<br />
https://radonc.ucsf.edu/jean-nakamura<br />
38 *<strong>UCSF</strong> authors in bold
Presentations<br />
Polygenic risk score for breast cancer risk prediction in Latinas: does one size fit all?<br />
Authors*: Elad Ziv<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 11:00 - 11:20 AM<br />
Location: Room 206, Level 2, Washington Convention Center<br />
Presentation: Major Symposium<br />
Ziv Research Interests: Dr. Ziv joined the faculty at <strong>UCSF</strong> in 2001. His group focuses on identifying genetic variations that<br />
underlie risk for malignancies by using insights from epidemiology and population genetics. A major interest has been<br />
genetic susceptibility to breast cancer among Latinas. Using a combination of admixture mapping and genome wide<br />
association, they have identified genetic variants that are unique among Latinas and are associated with strong protection<br />
against breast cancer susceptibility. They are currently using a whole exome sequencing approach to identify breast cancer risk<br />
variants among Latinas. Dr. Ziv’s group has successfully mapped the genes for ethnic neutropenia in African Americans. They<br />
are also currently studying the genetic variation underlying multiple myeloma susceptibility and progression.<br />
http://cancer.ucsf.edu/people/profiles/ziv_elad.3779<br />
__________________________________________________________________________<br />
“Weak links” in cancer proteostasis networks as new therapeutic targets<br />
Authors*: Martin Kampmann<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 10:30 - 12:30 PM<br />
Location: Marquis Ballroom Salons 1-2, Meeting Level 2, Marriott Marquis DC<br />
Presentation: Special Session<br />
Kampmann Research Interests: In our research, we ask how cells maintain their proteins in a functional and balanced state.<br />
In human cells, this is accomplished by a network of over 1,000 different factors called the proteostasis network. Our goal is<br />
to understand how this network functions, and how it is challenged and rewired in disease states, in particular cancer and<br />
neurodegenerative diseases. Our functional genomics technology, which integrates CRISPR/Cas9-based control of gene<br />
function and large-scale genetic interaction maps, enables us to elucidate dynamic networks and to pinpoint nodes that are<br />
potential therapeutic targets. We use biochemistry, biophysics and cell biology to “zoom in” on individual nodes of the network<br />
and to reveal their mechanism of action.<br />
http://kampmannlab.ucsf.edu<br />
39 *<strong>UCSF</strong> authors in bold
Presentations<br />
Minorities in Cancer Research Scientific Symposium: The Role of Diverse<br />
Populations in Precision Medicine<br />
Authors*: Laura Fejerman<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 10:30 - 12:30 PM<br />
Location: Room 206, Level 2, Washington Convention Center<br />
Presentation Type: Major Symposium<br />
Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute<br />
to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and<br />
breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her<br />
subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide<br />
association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions.<br />
Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.<br />
http://fejerman.ucsf.edu<br />
__________________________________________________________________________<br />
CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical<br />
activity in patients with advanced solid tumors<br />
Authors*: Leisha Emens, John Powderly, I2, Lawrence Fong, Joshua Brody, Patrick Forde, Matthew Hellmann, Brett Hughes,<br />
Shivaani Kummar, Sherene Loi, Jason Luke, Daruka Mahadevan, Benjamin Markman, Ian McCaffery, Richard Miller, Ginna Laport<br />
Presentation #: CT119<br />
Presentation Date/Time: April 4, 2017, 12:18 - 12:33 PM<br />
Location: Ballroom C, Level 3, Washington Convention Center<br />
Presentation: Clinical Trials Plenary Session<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring tumor<br />
immunotherapies in mouse models and in patients. Our primary focus is in immunotherapy of GI and GU malignancies.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor<br />
immunity both systemically and in the tumor microenvironment. Performing neoadjuvant immunotherapy trials, we determine<br />
how specific therapies can recruit immune effectors in cancer patients. Moreover, we have studied how clinical responders<br />
may differ from clinical non-responders. We are applying unbiased approaches to studying antigen-specific responses that<br />
are modulated in these patients and are currently developing biomarkers that may be predictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
40 *<strong>UCSF</strong> authors in bold
Presentations<br />
Vaccination in patients with low-grade glioma aiming at prevention of<br />
high-grade transformation<br />
Authors*: Hideho Okada<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 1:25 - 1:45 PM<br />
Location: Ballroom C, Level 3, Washington Convention Center<br />
Presentation: Rapid Advances in Prevention Research<br />
Okada Research Interests: As a translational physician scientist, Dr. Okada and his lab are focused on development of novel<br />
immunotherapeutic strategies for brain tumor patients. For example, Dr. Okada conducted one of the first immune gene therapy<br />
trials in patients with malignant glioma. His lab was also the first to identify and fully characterized cytotoxic T-lymphocyte<br />
epitopes for gliomas. Dr. Okada has also delineated the role of an integrin receptor very late activation antigen-4 and chemokine<br />
CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has integrated these findings to develop a number of<br />
vaccine trials in both adult and pediatric glioma patients. More recently, his group developed a novel chimeric antigen receptor<br />
targeting glioblastoma cells, and are currently conducting a pilot trial.<br />
http://neurosurgery.ucsf.edu/index.php/about_us_faculty_okada.html<br />
__________________________________________________________________________<br />
Overcoming kinase inhibitor resistance and dealing with biologic redundancy:<br />
mTOR and K-Ras<br />
Authors*: Kevan Michael Shokat<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 2:05 - 2:30 PM<br />
Location: Room 207, Level 2, Washington Convention Center<br />
Presentation: Major Symposium<br />
41 *<strong>UCSF</strong> authors in bold
Presentations<br />
Identifying allosteric modulators of KRas using second harmonic generation<br />
Authors*: Elizabeth Donohue Vo, Gabriel Besserer Mercado, Patrick Alexander, Ben Moree, Que Van, Andrew G. Stephen,<br />
Joshua Salafsky, Frank McCormick<br />
Presentation #: 4018<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 1<br />
Presentation: Poster Session/ Board #8<br />
__________________________________________________________________________<br />
Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase<br />
inhibitors using an oligonucleotide-based decoy<br />
Authors*: Christian Njatcha, Mariya Farooqui, Jennifer R. Grandis, Jill M. Siegfried<br />
Presentation #: 4101<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 4<br />
Presentation: Poster Session/ Board #11<br />
42 *<strong>UCSF</strong> authors in bold
Presentations<br />
Targeting IL-6 signaling overcomes cetuximab resistance in head and neck<br />
squamous cell carcinoma<br />
Authors*: Rachel A. O’Keefe, Neil Bhola, Toni M. Brand, Yan Zeng, Daniel E. Johnson, Jennifer R. Grandis<br />
Presentation #: 4108<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 4<br />
Presentation: Poster Session/ Board #18<br />
Grandis Research Interests: Cetuximab is an EGFR monoclonal antibody that is FDA-approved for the treatment of head and<br />
neck cancer. Despite ubiquitous over expression of EGFR in head and neck cancers, only a subset of patients respond to this<br />
drug and resistance mechanisms are incompletely understood. The Grandis lab has accumulated evidence that secretion of<br />
interleukin 6 (IL6), with subsequent oncogenic signaling represents a potential pathway of cetuximab resistance where<br />
co-targeting IL6/ILR-receptor may represent a plausible therapeutic strategy.<br />
http://cancer.ucsf.edu/people/profiles/grandis_jennifer.6048<br />
__________________________________________________________________________<br />
Application of convolutional neural networks to breast biopsies to uncover tissue<br />
correlates of mammographic breast density<br />
Authors*: Maeve Mullooly, Babak Ehteshami Bejnordi, Maya Palakal, Pamela M. Vacek, Donald L. Weaver, John A. Shepherd,<br />
Bo Fan, Amir Pasha Mahmoudzadeh, Jeff Wang, Jason M. Johnson, Sally D. Herschorn, Brian L. Sprague, Ruth M. Pfeiffer,<br />
Louise A. Brinton, Mark E. Sherman, Andrew Beck, Gretchen L. Gierach<br />
Presentation #: 4235<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 11<br />
Presentation: Poster Session/ Board #1<br />
Shepherd Research Interests: Dr. Shepherd’s research interests involve quantitative imaging methods for tissue<br />
composition using x-rays. His mammographic methods are used extensively for research around the world and in the<br />
San Francisco Mammography Registry Program. Dr. Shepherd’s efforts are focused on the technical imaging aspects of<br />
the measurements of the body composition and the translation of these measurements into different fields of study. He has<br />
present and future research projects in the following areas: breast cancer risk and detection using breast density and tissue<br />
texture measures; dual-energy x-ray diagnostic mammography for characterizing compositional signatures of cancer lesions;<br />
total body protein measures, body shape analysis and metabolic diseases; statistics of quality assurance and quality<br />
control for quantitative measurements.<br />
https://radiology.ucsf.edu/people/john-shepherd<br />
43 *<strong>UCSF</strong> authors in bold
Presentations<br />
Exosomal miR-3622a as prognostic marker in prostate cancer<br />
Authors*: Thao Yang, Divya Bhagirath, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Varahram Shahryari,<br />
Marisa Shiina, Yutaka Hashimoto, Priyanka Kulkarni, Pritha Dasgupta, Mitsuho Imai-Sumida, Soichiro Yamamura,<br />
Z Laura Tabatabai, Kirsten Greene, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng, Sharanjot Saini<br />
Presentation #: 4435<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 18<br />
Presentation: Poster Session/ Board #13<br />
Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression,<br />
recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the disease.<br />
Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate cancer<br />
progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated molecular<br />
pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers for the disease.<br />
We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the regulatory role of key<br />
microRNAs in prostate cancer stem cells.<br />
https://www.ncire.org/research/researchers_by_name/Sharanjot-Saini-PhD/<br />
__________________________________________________________________________<br />
KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Interacting Kinases<br />
(MNKs) in a PI3K-dependent, AKT-independent manner<br />
Authors*: Jillian M. Silva, Rachel K. Bagni, Davide Ruggero, Frank McCormick<br />
Presentation #: 4484<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 21<br />
Presentation: Poster Session/ Board #17<br />
44 *<strong>UCSF</strong> authors in bold
Presentations<br />
Preclinical investigation of SGN-CD70A antibody-drug conjugate in<br />
T cell lymphomas<br />
Authors*: Chen-Yen Yang, Linlin Wang, Laura Pincus, Frank McCormick, Ryan Gill, Wei Ai<br />
Presentation #: 4589<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 26<br />
Presentation: Poster Session/ Board #4<br />
__________________________________________________________________________<br />
Omx a hypoxia modulator reverses the immunosuppressive glioblastoma<br />
microenvironment by stimulating T cell infiltration and activation that results in<br />
increased number of long-term survivors<br />
Authors*: Natacha Le Moan, Philberta Leung, Sarah Ng, Tina Davis, Carol Liang, Jonathan W. Winger, Stephen P. L. Cary,<br />
Nicolas Butowski, Ana Krtolica<br />
Presentation #: 4686<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 30<br />
Presentation: Poster Session/ Board #2<br />
Butowski Research Interests: My research includes translational research and a wide range of clinical trials, including those<br />
with convection-enhanced delivery (CED) with real-time MRI imaging, targeted agents, immunotherapy, and combination<br />
strategies. I am the Director of Translational Research in Neuro-Oncology and lead the translational effort on behalf of the<br />
<strong>UCSF</strong> Brain Tumor Research Center and Preclinical Core. My work has helped to create the groundwork for allied research<br />
in neuro-oncology and an extensive <strong>UCSF</strong> clinical trial portfolio for patients with primary brain and spine tumors, including<br />
an assortment of immunotherapy trials and surgically based trials. I have also designed investigator initiated trials, including<br />
a clinical trial employing intratumoral delivery with real-time MRI imaging as well as those with a range of novel targets,<br />
molecular markers and imaging biomarkers. I have also authored a number of peer-reviewed papers and presented work at<br />
national and international meetings.<br />
https://www.ucsfhealth.org/nicholas.butowski<br />
45 *<strong>UCSF</strong> authors in bold
Presentations<br />
Metronomic chemotherapy prevents therapy-induced stromal activation and<br />
induction of cancer stem cells<br />
Authors*: Kelvin K. Tsai, Tze-Sian Chan, Chung-Chi Hsu, Vincent C. Pai, Shenq-Shyang Huang, Valerie M. Weaver<br />
Presentation #: 4763<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 37<br />
Presentation: Poster Session/ Board #1<br />
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences<br />
cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins,<br />
syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate<br />
cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and<br />
organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into<br />
two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor<br />
progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.<br />
http://weaverlab.ucsf.edu<br />
__________________________________________________________________________<br />
A pan-cancer analysis framework for incorporating gene expression information<br />
into clinical interpretation of pediatric cancer genomic data<br />
Authors*: Olena Morozova, Yulia Newton, Avanthi Tayi Shah, Holly Beale, Du Linh Lam, John Vivian, Isabel Bjork,<br />
Theodore Goldstein, Josh Stuart, Sofie Salama, E. Alejandro Sweet-Cordero, David Haussler<br />
Presentation #: 4890<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 42<br />
Presentation: Poster Session/ Board #24<br />
Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic<br />
mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and<br />
human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that<br />
regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy.<br />
We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of<br />
chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role<br />
for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in<br />
NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work,<br />
we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.<br />
https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106<br />
46 *<strong>UCSF</strong> authors in bold
Presentations<br />
Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer<br />
Authors*: Emanuela Dylgjeri, Jonathan F. Goodwin, Christopher M. McNair, Ayesha A. Shafi, Vishal Kothari, Felix Feng,<br />
Dana Rathkop, Karen Knudsen<br />
Presentation #: LB-264<br />
Presentation Date/Time: April 4, 2017, 1:00 pm - 5:00 pm<br />
Location: Section 35<br />
Presentation: Poster Session/ Board #3<br />
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s<br />
research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment<br />
resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological<br />
perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular<br />
biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive<br />
disease progression, and 3) to develop therapeutic approaches to target these disease drivers.<br />
https://radonc.ucsf.edu/felix-feng<br />
__________________________________________________________________________<br />
Technologies for Defining the Cancer Interactome<br />
Authors*: Nevan J. Krogan<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 2:45 - 4:45 PM<br />
Location: Marquis Ballroom Salons 3-4, Meeting Level 2, Marriott Marquis DC<br />
Presentation: NIH Sponsored Session<br />
Krogan Research Interests: Research in the Krogan lab focuses on high-throughput network biology to derive mechanistic<br />
insights into cellular processes and disease conditions, with a particular emphasis on cancer, pathogenesis, psychiatric<br />
disorders and heart disease. Cancer research and treatment is increasingly dependent on knowledge of biological networks<br />
of multiple types, including physical interactions among proteins and synthetic-lethal and epistatic interactions among<br />
genes. Dr. Krogan is Co-Director of the Cancer Cell Map Initiative (CCMI), which aims to comprehensively detail these<br />
complex interactions among cancer genes and proteins using a combination of physical interaction, genetic interaction, and<br />
computational approaches. This work will enable the analysis of cancer molecular networks with a view towards pathway<br />
and network-based personalized therapy.<br />
http://kroganlab.ucsf.edu<br />
47 *<strong>UCSF</strong> authors in bold
Presentations<br />
Computational detection of oncogene‐centric pathway members<br />
Authors*: Joshua Broyde, David Simpson, Diana Murray, Alexander Lachmann, Federico M. Giorgi, Barry Honig,<br />
Alejandro E. Sweet-Cordero, Andrea Califano<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 4:05 – 4:20<br />
Location: Room 147, Level 1, Washington Convention Center<br />
Presentation: Minisymposium<br />
Sweet-Cordero Research Interests: My lab works to identify novel therapeutic approaches for cancer that target the genetic<br />
mutations and altered signaling networks specific to cancer cells. We use functional genomics applied to mouse and<br />
human systems (genetically engineered models, patient derived xenografts) to understand the transcriptional networks that<br />
regulate the outcome of specific oncogenic mutations and to understand how cancers become resistant to chemotherapy.<br />
We have two primary disease interests: lung cancer and pediatric sarcomas. Our lab has identified novel regulators of<br />
chemoresistance in lung cancer. We have used functional genomics in mouse and human models to identify a novel role<br />
for Wt1 in mediating KRAS-driven oncogenesis. We have identified and characterized the role of tumor-propagating cells in<br />
NSCLC and identified a key role for Notch3 as a self-renewal pathway in mouse and human NSCLC. In our sarcoma work,<br />
we are interested in mechanisms driving osteosarcoma and Ewing sarcoma progression.<br />
https://cancer.ucsf.edu/people/profiles/sweetcordero_alejandro.8106<br />
__________________________________________________________________________<br />
Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients<br />
Authors*: Sabine Mueller, Charles G. Mullighan - Invited Speakers<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM<br />
Location: Room 150, Level 1, Washington Convention Center<br />
Presentation: Forum<br />
Mueller Research Interests: The laboratory of Dr. Sabine Mueller focuses on translational research in pediatric neuro-oncology.<br />
A key focus is the development and characterization of patient derived xenograft (PDX) models for diffuse intrinsic pontine<br />
gliomas (DIPG) and other pediatric high grade gliomas (pHGGs). In particular, the Mueller lab investigates the genomic<br />
heterogeneity of DIPGs and other pHGGs. Additionally, they are exploring the utility of liquid biopsies by assessing circulating<br />
tumor DNA and correlating this with disease response. Further, the laboratory is exploring central nervous system (CNS)<br />
directed delivery strategies, such as convection enhanced delivery (CED) in combination with nanotechnology, in these PDX<br />
models. The laboratory has several industry partnerships to test new agents as single agents and in combination therapy<br />
strategies with other agents as well as radiation therapy.<br />
http://cancer.ucsf.edu/people/profiles/mueller_sabine.4800<br />
48 *<strong>UCSF</strong> authors in bold
Presentations<br />
Early Detection of Lethal Cancers: Separating the Wheat from the Chaff<br />
Authors*: Avrum E. Spira, Laura J. Esserman - Invited Speakers<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM<br />
Location: East Salon A-B, Level 1, Washington Convention Center<br />
Presentation: Forum<br />
__________________________________________________________________________<br />
Genomics and the Environment: Moving toward Precision Medicine in the Context<br />
of Health Disparities<br />
Authors*: Laura Fejerman<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 5:00 - 6:30 PM<br />
Location: Room 152, Level 1, Washington Convention Center<br />
Presentation Type: Forum<br />
Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute<br />
to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and<br />
breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her<br />
subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide<br />
association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions.<br />
Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.<br />
http://fejerman.ucsf.edu<br />
49 *<strong>UCSF</strong> authors in bold
Presentations<br />
Spatial-mechanical regulation of tumor dormancy and metastases<br />
Authors*: Valerie M Weaver<br />
Presentation #:<br />
Presentation Date/Time: April 4, 2017, 6:50 - 7:10 PM<br />
Location: Marquis Ballroom Salons 6-10, Meeting Level 2, Marriott Marquis DC<br />
Presentation: Town Meeting<br />
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences<br />
cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins,<br />
syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate<br />
cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and<br />
organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into<br />
two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor<br />
progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.<br />
http://weaverlab.ucsf.edu<br />
50 *<strong>UCSF</strong> authors in bold
Presentations<br />
Wednesday, April 5, 2017<br />
Breast cancer characteristics among Indigenous American women from Peru<br />
Authors*: Lizeth I. Tamayo, Tatiana Vidaurr2, Jeannie N. Vásquez, Sandro Casavilca, Jessica I. A. Palomino, Monica Calderon,<br />
Garth H. Rauscher, Laura Fejerman<br />
Presentation #: 5275<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 12<br />
Presentation: Poster Session/ Board #3<br />
Fejerman Research Interests: Dr. Fejerman focuses on the discovery of genetic and non-genetic factors that contribute<br />
to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and<br />
breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her<br />
subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide<br />
association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions.<br />
Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.<br />
http://fejerman.ucsf.edu<br />
__________________________________________________________________________<br />
Association of physical activity with risk of prostate cancer defined by<br />
TMPRSS2:ERG<br />
Authors*: Claire H. Pernar, Ericka M. Ebot, Andreas Pettersson, Rebecca E. Graff, Thomas U. Ahearn, Amparo G. Gonzalez-Feliciano,<br />
Sarah C. Markt, Kathryn M. Wilson, Stephen Finn, Michelangelo Fiorentino, Edward L. Giovannucci, Lorelei A. Mucci<br />
Presentation #: 5317<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 13<br />
Presentation: Poster Session/ Board #15<br />
Witte Research Interests: Our research program encompasses a synthesis of methodological and applied genetic<br />
epidemiology, with the overall aim of deciphering the mechanisms underlying complex diseases and traits (Witte, Visscher &<br />
Wray, Nature Reviews Genetics 2014). Our methods work is focused on the design and statistical analysis of next-generation<br />
sequencing and genetic association studies. We are applying these methods to studies of cancer (e.g., of the prostate), birth<br />
defects, and pharmacogenomics.<br />
http://wittelab.ucsf.edu/pages/research<br />
51 *<strong>UCSF</strong> authors in bold
Presentations<br />
An exosomal biomarker for prostate cancer<br />
Authors*: Divya Bhagirath, Thao Yang, Kirandeep Sekhon, Nathan Bucay, Shahana Majid, Yutaka Hashimoto,<br />
Priyanka Kulkarni, Pritha Dasgupta, Marisa Shiina, Varahram Shahryari, Mitsuho Imai-Sumida, Soichiro Yamamura,<br />
Z Laura Tabatabai, Yuichiro Tanaka, Rajvir Dahiya, Guoren Deng, Sharanjot Saini.<br />
Presentation #: 5448<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 19<br />
Presentation: Poster Session/ Board #13<br />
Saini Research Interests: A major clinical challenge in prostate cancer is the elucidation of pathways of tumor progression,<br />
recurrence and metastasis, which could lead to the design of better diagnostic and therapeutic strategies against the<br />
disease. Towards this, our current research is primarily focused on delineating the molecular mechanisms driving prostate<br />
cancer progression, recurrence and metastasis. We are particularly interested in understanding key microRNA-mediated<br />
molecular pathways in prostate cancer with a long term objective of development of microRNAs as alternative biomarkers<br />
for the disease. We have identified important microRNA regulators of prostate cancer metastasis and also elucidated the<br />
regulatory role of key microRNAs in prostate cancer stem cells.<br />
https://www.ncire.org/research/researchers_by_name/Sharanjot-Saini-PhD/<br />
__________________________________________________________________________<br />
VCAN promotes clear cell renal cell carcinoma tumor progression and metastasis,<br />
and predicts poor prognosis<br />
Authors*: Yozo Mitsui, Taku Kato, Shigekatsu Maekawa, Yutaka Hashimoto, Marisa Shiina, Mitsuho Imai Sumida,<br />
Ryan Kenji Wong, Soichiro Yamamura, Varahram Shahryari, Shahana Majid, Sharanjot Saini, Guoren Deng,<br />
Rajvir Dahiya, Koichi Nakajima, Yuichiro Tanaka<br />
Presentation #: 5749<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 37<br />
Presentation: Poster Session/ Board #13<br />
Tanaka Research Interests: Dr. Tanaka’s research at the UC/VA Urology Research Center San Francisco over the years has<br />
involved a variety of areas that include methylation, polymorphism, non-coding RNA, aging, gene function and signaling<br />
pathways. Specifically, his research focuses on finding risk factors for urological cancers by utilizing human specimens,<br />
assessing the functional role of these biomarkers at the cellular and molecular levels and use of animal models, and<br />
determining its regulation in the cell; as he attempts to understand the mechanisms of the carcinogenesis process. The<br />
cancer types that he’s been studying involve prostate, kidney and bladder. By engaging in his research interest, results can<br />
lead to biomarkers as well as potential therapeutic implications for urological cancers.<br />
https://www.ncire.org/research/researchers_by_name/Yuichiro-Tanaka-PhD/<br />
52 *<strong>UCSF</strong> authors in bold
Presentations<br />
Disrupting the Aurora kinase A interactome in pediatric cancer<br />
Authors*: Sucheta Mukherjee, Carolyn Tu, Clay Gustafson<br />
Presentation #: 5818<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 40<br />
Presentation: Poster Session/ Board #4<br />
Gustafon Research Interests: The Gustafson lab focuses on new basic biological discoveries in cancer and leveraging<br />
these to develop novel therapies. One focus has been the discovery and development of novel targeted therapies to treat<br />
MYC driven cancers, particularly neuroblastoma. Pathways which regulate MYC proteins are central to neuroblastoma, as<br />
well as a wide array of other pediatric and adult cancers. MYCN is prominently amplified in high-risk neuroblastoma and<br />
neuroblastoma is widely considered a model MYC-protein driven disease. Most recently we have discovered a new class<br />
of conformation-disrupting Aurora A inhibitors (CD-AURKi) with CD532 as our lead compound. These CD-AURKi potently<br />
inhibit Aurora Kinase A and downregulates MYCN protein in neuroblastoma cells. Using co-crystal structures, cell culture<br />
models, and structure-activity relationships, we have shown that CD532 acts via a novel allosteric mechanism whereby a<br />
kinase inhibitor is used to drug an undruggable transcription factor.<br />
http://gustafsonlab.ucsf.edu<br />
__________________________________________________________________________<br />
Androgen receptor (AR): A novel target for radiosensitization in triple-negative<br />
breast cancers (TNBC)<br />
Authors*: Benjamin C. Chandler, Corey W. Speers, Shuang G. Zhao, Meilan Liu, Kari Wilder-Romans, Eric Olsen, Shyam Nyati,<br />
Daniel Spratt, Daniel Wahl, Daniel Hayes, Felix Y. Feng, Lori J. Pierce<br />
Presentation #: 5839<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 41<br />
Presentation: Poster Session/ Board #2<br />
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s<br />
research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment<br />
resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological<br />
perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular<br />
biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive<br />
disease progression, and 3) to develop therapeutic approaches to target these disease drivers.<br />
https://radonc.ucsf.edu/felix-feng<br />
53 *<strong>UCSF</strong> authors in bold
Presentations<br />
Cdk4/6 kinase inhibitor resistance in prostate cancer<br />
Authors*: Renee de Leeuw, Matthew J. Schiewer, Christopher McNair, Michael A. Augello, Akihiro Yoshida, Edward S. Hazard,<br />
Sean Courtney, Gerard T. Hardiman, Justin Drake, Felix Y. Feng, Scott Tomlins, Maha H. Hussain, J. Alan Diehl, William K. Kelly,<br />
Karen E. Knudsen<br />
Presentation #: 5874<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 42<br />
Presentation: Poster Session/ Board #9<br />
Feng Research Interests: Dr. Felix Feng is a leader in translational research in prostate cancer. The primary aim of Dr. Feng’s<br />
research program is to individualize therapy for patients with aggressive disease, by identifying determinants of treatment<br />
resistance and developing strategies to overcome this resistance. To enhance current clinical approaches from a biological<br />
perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular<br />
biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive<br />
disease progression, and 3) to develop therapeutic approaches to target these disease drivers.<br />
https://radonc.ucsf.edu/felix-feng<br />
__________________________________________________________________________<br />
Tumor microenvironment modulates RTK signaling<br />
Authors*: Dhruv Thakar, Shalini T. Low-Nam, Jay T. Groves, Valerie M. Weaver<br />
Presentation #: 5912<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 43<br />
Presentation: Poster Session/ Board #24<br />
Weaver Research Interests: The extracellular matrix (ECM), the noncellular component of the microenvironment, influences<br />
cell growth, survival, migration and tissue-specific differentiation through a repertoire of cellular receptors including integrins,<br />
syndecans and discoidin receptors. We are exploring the molecular mechanisms whereby these ECM receptors modulate<br />
cell fate: specifically, how mechanical and topological properties of the matrix, which are related to its composition and<br />
organization, regulate the function of matrix receptors to alter cell behavior. Our research program is broadly divided into<br />
two fields of inquiry: (1) how matrix composition and organization influences mammary tissue development and tumor<br />
progression and (2) to clarify the role of matrix force on embryonic and adult stem cell fate.<br />
http://weaverlab.ucsf.edu<br />
54 *<strong>UCSF</strong> authors in bold
Presentations<br />
A novel oncomiR negatively regulates PTEN pathway in prostate cancer<br />
Authors*: Nadeem S. Bhat, Melissa Colden, Prerna Arora, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari,<br />
Soichiro Yamamura, Yuichiro Tanaka, Taku Katu, Yutaka Hashimoto, Marisa Shiina, Priyanka Kulkarni,<br />
Pritha Dasgupta, Mitsuho Imai-sumida, Shigekatsu Maekawa, Guoren Deng, Rajvir Dahiya, Shahana Majid<br />
Presentation #: LB-326<br />
Presentation Date/Time: April 5, 2017, 8:00 am - 12:00 noon<br />
Location: Section 36<br />
Presentation: Poster Session/ Board #12<br />
Majid Research Interests: The Majid lab, located Urology Research Center at the VAMC/<strong>UCSF</strong>, focuses in the area of urological<br />
cancers to understand the etiology and to develop novel molecular biomarkers for initiation, progression and metastasis with<br />
special emphasis on prostate cancer. We have been working in the field of microRNAs, genetics and epigenetics of urologic<br />
cancers. Cancer progression markers are identified by employing genome-wide approaches, and utilizing cells culture and<br />
mouse models as well as tissues from patients. The objective of the lab is to identify novel therapeutic targets or valuable<br />
biomarkers to establish rational therapeutic strategies for the diagnosis and treatment of cancer.<br />
http://profiles.ucsf.edu/shahana.majid<br />
__________________________________________________________________________<br />
Glioblastoma: Where we are, where we have been, and what is next<br />
Authors*: Michael Prados<br />
Presentation #:<br />
Presentation Date/Time: April 5, 2017, 10:15 - 10:30 AM<br />
Location: Room 145, Level 1, Washington Convention Center<br />
Presentation: Recent Advances in Organ Site Research<br />
Prados Research Interests: Dr. Prados is a world-recognized Neuro-oncology expert. He led the Adult Brain Tumor Consortium<br />
for over 15 years and founded the Pacific Pediatric Neuro-Oncology Consortium (PNOC), a multi-institutional consortium<br />
of now 15 major academic centers across the United States. Currently Dr. Prados is Professor Emeritus at <strong>UCSF</strong> devoting<br />
his efforts towards pediatric Neuro-Oncology clinical and translational research. He is the co-Project Leader of a pediatric<br />
brain tumor SPORE project at <strong>UCSF</strong> and is co-Project Leader of the PNOC. His major interests are early phase clinical trials<br />
research and the translational studies that precede and inform those trials in both adults and children. He is part of the Editorial<br />
board of Neuro-Oncology, Journal of Neuro-Oncology and Journal of Clinical Oncology, and a member of the NCI/CTEP Brain<br />
Malignancies Steering Committee. In 2014 he was awarded the Victor Levin Award for lifetime clinical research excellence from<br />
the Society of Neuro-Oncology.<br />
http://cancer.ucsf.edu/people/profiles/prados_michael.3603<br />
55 *<strong>UCSF</strong> authors in bold
Summary of Abstracts<br />
Summary of Abstracts<br />
by Faculty Member<br />
Rahul Aggarwal, MD<br />
CT091<br />
Wei Ai, MD<br />
Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in<br />
subjects with solid tumors<br />
4589 Preclinical investigation of SGN-CD70A antibody-drug conjugate in T cell lymphomas<br />
Mary Helen Barcellos-Hoff, PhD<br />
831 TGFβ controls the DNA damage response via miR-182 regulation of BRCA1 and ATM<br />
Neil Bhola, PhD<br />
95 Targeting BRD4 overcomes cetuximab resistance in HNSCC<br />
Trever Bivona, MD, PhD<br />
— Mechanisms of residual disease during targeted therapy<br />
LB-124<br />
COP1 E3 ligase modulates response to oncogenic MAPK pathway<br />
Collin Blakely, MD<br />
CT060<br />
STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or<br />
metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions<br />
Jeffrey Bluestone, PhD<br />
683A<br />
Mechanism of liver metastasis induced systemic suppression of checkpoint inhibitor response<br />
Nicolas Butowski, MD<br />
4686 Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating<br />
T cell infiltration and activation that results in increased number of long-term survivors<br />
Atul Butte, MD, PhD<br />
— Characterizing tumor-adjacent normal tissue: Is it really normal?<br />
LB-006<br />
Oncology model fidelity scores<br />
Rajvir Dahiya, PhD<br />
462 The role of miR-24 as a race-related genetic factor in prostate cancer<br />
483 Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness<br />
between African Americans and Caucasians<br />
56
Summary of Abstracts<br />
Adil Daud, MD<br />
— Response to checkpoint therapy and exhausted CTL in the tumor microenvironment<br />
Michel DuPage, PhD<br />
1014 Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity<br />
Laura Esserman, MD, MBA<br />
— Early Detection of Lethal Cancers: Separating the Wheat from the Chaff<br />
Laura Fejerman, PhD<br />
— Genomics and the Environment: Moving toward Precision Medicine in the Context of Health Disparities<br />
— Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine<br />
5275 Breast cancer characteristics among Indigenous American women from Peru<br />
Felix Feng, MD<br />
2546 The long noncoding RNA SChLAP1 inhibits the SWI/SNF complex, revealing a therapeutic opportunity in<br />
prostate cancer<br />
5839 Androgen receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC)<br />
5874 Cdk4/6 kinase inhibitor resistance in prostate cancer<br />
LB-086<br />
LB-264<br />
PARP-1 controls the DNA damage response by regulating E2F1 transcriptional activity<br />
Preclinical evaluation of DNA-PK as a therapeutic target in prostate cancer<br />
Lawrence Fong, MD<br />
549 Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate<br />
cancer patients<br />
1694 Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor<br />
diversity in localized and metastatic prostate cancer patients<br />
CT031<br />
CT119<br />
A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients<br />
with metastatic castrate-resistant prostate cancer (mCRPC)<br />
CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with<br />
advanced solid tumors<br />
Jason Gestwicki, PhD<br />
1180 Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer<br />
Jennifer Grandis, MD<br />
— Precision medicine lessons from window-of-opportunity trials<br />
1779 Chronic NSAID use increases survival in PIK3CA-altered head and neck squamous cell carcinoma<br />
4101 Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an<br />
oligonucleotide-based decoy<br />
4108 Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma<br />
57
Summary of Abstracts<br />
Clay Gustafson, MD, PhD<br />
5818 Disrupting the Aurora kinase A interactome in pediatric cancer<br />
Patrick Ha, MD<br />
3577 Splice expression variation analysis (SEVA) for differential gene isoform usage in cancer<br />
Tonya Kaltenbach, MD<br />
281 Site specific risk factors for colorectal cancer<br />
Martin Kampmann, PhD<br />
— “Weak links” in cancer proteostasis networks as new therapeutic targets<br />
Nevan Krogan, PhD<br />
— Technologies for Defining the Cancer Interactome<br />
Mignon Loh, MD<br />
2642 Preclinical efficacy of daratumumab in acute lymphoblastic leukemia<br />
Shahana Majid, PhD<br />
LB-326<br />
A novel oncomiR negatively regulates PTEN pathway in prostate cancer<br />
Frank McCormick, PhD<br />
435 Regulation of macropinocytosis-dependent cell survival in pancreatic cancer cells<br />
— The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research<br />
1209 FGFR inhibition re-sensitizes BRAF/MEK dual resistant cells to the BRAF/MEK inhibitor combination<br />
1366 Structural basis of impaired GTP hydrolysis in oncogenic mutants of KRAS<br />
1370 EGFR-mediated Spred1 phosphorylation inhibits NF1 to sustain constitutive Ras/MAPK signaling<br />
3182 Cytoskeletal modulation results in increased tumor survival and drug resistance through attenuation of<br />
p53 dependent apoptosis<br />
4018 Identifying allosteric modulators of KRas using second harmonic generation<br />
4484 KRAS regulates eIF4E Binding Proteins (4EBPs) via MAPK-Interacting Kinases (MNKs) in a PI3K-dependent,<br />
AKT-independent manner<br />
Michael McManus, PhD<br />
1006 Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition<br />
Sabine Mueller, MD<br />
— Precision Medicine: Will It Be of Benefit in Pediatric Cancer Patients<br />
58
Summary of Abstracts<br />
Pamela Munster, MD<br />
CT087<br />
Ribociclib + endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR+), human epidermal<br />
growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of<br />
molecular alterations<br />
Jean Nakamura, MD<br />
1356 Variable drug responses characterize the functional heterogeneity of Nf1 null tumors<br />
— Post-radiation mutational signatures<br />
Hideho Okada, MD, PhD<br />
— Brain cancer immunotherapy<br />
3767 Identification of a novel and a shared H3.3K27M mutation derived neoantigen epitope and H3.3K27M specific TCR<br />
engineered T cell therapy for glioma<br />
— Vaccination in patients with low-grade glioma aiming at prevention of high-grade transformation<br />
Susana Ortiz-Urda, MD<br />
3493 LncRNA as potential target in drug-resistant melanomas<br />
Melike Pekmezci, MD<br />
3863 A subset of poorly prognostic pediatric posterior fossa ependymomas exhibit lowered H3K27me3 and DNA<br />
hypomethylation and show epigenetic similarities with H3K27M mutant diffuse intrinsic pontine gliomas<br />
Claudia Petritsch, PhD<br />
916 Asymmetric cell division regulator prevents hyperproliferation in glioma cell-of-origin<br />
Michael Prados, MD<br />
LB-008<br />
The Pediatric Brain Tumor Atlas: building an integrated, multi-platform data-rich ecosystem for collaborative<br />
discovery in the cloud<br />
— Glioblastoma: Where we are, where we have been, and what is next<br />
Davide Ruggero, PhD<br />
— Translating the cancer genome one codon at a time and its therapeutic implications<br />
Hope Rugo, MD<br />
— Transforming breast cancer treatment with CDK4/6 inhibitors<br />
CT044<br />
MONARCH 1: Final overall survival analysis of a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor,<br />
as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease<br />
Amit Sabnis, MD<br />
CT030<br />
STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and<br />
primary CNS tumors, with or without TRK, ROS1, or ALK fusions<br />
59
Summary of Abstracts<br />
Sharanjot Saini, PhD<br />
4435 Exosomal miR-3622a as prognostic marker in prostate cancer<br />
5448 An exosomal biomarker for prostate cancer<br />
John Shepherd, PhD<br />
4235 Application of convolutional neural networks to breast biopsies to uncover tissue correlates of<br />
mammographic breast density<br />
Kevan Shokat, PhD<br />
— Overcoming kinase inhibitor resistance and dealing with biologic redundancy: mTOR and K-Ras<br />
Erin Simonds, PhD<br />
3693 Single cell RNA-Seq of primary lymphomas reveals the diverse transcriptional states of the cancer<br />
immunologic milieu<br />
Alejandro Sweet-Cordero, MD<br />
1948 Tumor-specific copy number alterations uncover therapeutic opportunities in osteosarcoma<br />
4890 A pan-cancer analysis framework for incorporating gene expression information into clinical interpretation of<br />
pediatric cancer genomic data<br />
— Computational detection of oncogene‐centric pathway members<br />
Eric Talevich, PhD<br />
LB-044<br />
Copy number estimation from targeted amplicon-based next-generation sequencing of castration-resistant<br />
prostate cancer biopsies: analytic validation and clinical qualification for a iPARP clinical trial<br />
Yuichiro Tanaka, PhD<br />
2288 Effects of tobacco smoking and alcohol consumption on risks of CYP1B1 polymorphisms for prostate cancer<br />
5749 VCAN promotes clear cell renal cell carcinoma tumor progression and metastasis, and predicts poor prognosis<br />
Margaret Tempero, MD<br />
— A beginner’s guide to perplexing clinical issues in pancreatic adenocarcinoma<br />
Laura van’t Veer, PhD<br />
LB-102<br />
Landscape analysis of the initial data release from AACR Project GENIE<br />
Kyle Walsh, PhD<br />
1320 Non-additive and interaction effects of HLA class 2 polymorphism contributing to risk of glioma<br />
60
Summary of Abstracts<br />
Valerie Weaver, PhD<br />
— Tissue Tension: The extracellular martrix and PDAC phenotype<br />
— Forcing tumor progression and aggression<br />
3985 NCoR2 regulates glioblastoma progression and treatment resistance<br />
4763 Metronomic chemotherapy prevents therapy-induced stromal activation and induction of cancer stem cells<br />
— Spatial-mechanical regulation of tumor dormancy and metastases<br />
5912 Tumor microenvironment modulates RTK signaling<br />
Jonathan Weissman, PhD<br />
— Retooling CRISPR to turn genes on and off<br />
Joseph Wiemels, PhD<br />
1273 Pathway analysis of insulin-like growth factor candidate genes and risk of pediatric rhabdomyosarcoma<br />
2263 Neonatal hormone levels and risk of testicular germ cell tumors (TGCT)<br />
John Witte, PhD<br />
1297 Genetic reclassification of prostate-specific antigen levels for personalized prostate cancer screening<br />
1310 Identification of pleiotropic cancer susceptibility variants from genome-wide association studies reveals<br />
functional characteristics<br />
1316 Germline genetic signals across multiple aggressive prostate cancer phenotypes<br />
5317 Association of physical activity with risk of prostate cancer defined by TMPRSS2:ERG<br />
Soichiro Yamamura, PhD<br />
199 Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways<br />
3449 Genistein inhibits renal cancer progression through long non-coding RNA HOTAIR suppression<br />
Elad Ziv, MD<br />
— Polygenic risk score for breast cancer risk prediction in Latinas: does one size fit all?<br />
Lani Wu, PhD/Steven Altschuler, PhD<br />
3950 A novel combination therapy targeting BCL6 and phospho-STAT3 defeats intratumor heterogeneity in a subset<br />
of non-small cell lung cancers<br />
61